

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/10799 A1

(51) International Patent Classification⁷: C07B 61/00,
C07C 237/22, 231/14, C07D 207/26, 233/54, 241/44,
401/04, 403/04, 403/06, 405/06, 409/06

(21) International Application Number: PCT/US00/21257

(22) International Filing Date: 3 August 2000 (03.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/368,213 4 August 1999 (04.08.1999) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/368,213 (CON)
Filed on Not furnished

(71) Applicant (for all designated States except US): AVEN-
TIS PHARMACEUTICAL PRODUCTS INC. [US/US];
Route 202-206, P.O. Box 6800, Mail Code: EMC-G1,
Bridgewater, NJ 088070-0800 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HULME, Christo-
pher [US/US]; 970 Township Line Road, Phoenixville,
PA 19460 (US). MORTON, George, C. [US/US]; 313
Ross Lane, Collegeville, PA 19426 (US). SALVINO,
Joseph, M. [US/US]; 272 Second Street, Schwenksville,
PA 19473 (US). LABAUDINIÈRE, Richard, F. [FR/US];
220 Richard Way, Collegeville, PA 19426 (US). MASON,

Helen, J. [GB/US]; 4 Eagle Creek Court, Skillman, NJ
08558 (US). MORRISSETTE, Mathew, M. [US/US];
1922 Linda Lane, Pottstown, PA 19464 (US). MA, Liang
[CN/US]; 251 West Dekalb Pike. E214, King of Prussia,
PA 19406 (US). CHERRIER, Marie-Pierre [FR/US];
The Village Of Pickering Run C-5, 800 Kimberton Road,
Phoenixville, PA 19460 (US).

(74) Agents: NEWMAN, Irving et al.; Aventis Pharmaceutical
Products Inc., Route 202-206, P.O. Box 6800, Mail Code:
EMC-G1, Bridgewater, NJ 088070-0800 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR PREPARING N-[(ALIPHATIC OR AROMATIC)CARBONYL]-2-AMINOACETAMIDE
COMPOUNDS AND FOR CYCLIZING SUCH COMPOUNDS

(57) Abstract: A method for preparing an N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound, and for preparing a
cyclized compound therefrom, as well as novel resin bound intermediate compounds that are useful for preparing such compounds.

WO 01/10799 A1

METHODS FOR PREPARING N-[(ALIPHATIC OR AROMATIC)CARBONYL)]-2-AMINOACETAMIDE COMPOUNDS AND FOR CYCLIZING SUCH COMPOUNDS

5 This application is a continuation-in-part of U.S. patent application No. 09/368,213 filed on August 4, 1999, which is a continuation-in-part of International Patent Application No. PCT/US99/01923, filed on January 29, 1999, which is, in turn, a continuation-in-part of U.S. Provisional Patent Application No. 60/101,056, filed September 18, 1998, U.S. Provisional Patent Application No. 60/098,708, filed September 1, 1998, U.S. Patent Application No. 10 60/098,404, filed August 31, 1998, and U.S. Provisional Patent Application No. 60/073,007, filed January 29, 1998, now abandoned.

This invention is directed to a method for preparing an N-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compound, and for preparing a cyclized compound therefrom, as well as to the novel resin bound intermediate compounds that are useful for 15 preparing such compounds.

Background of the Invention

1,4-benzodiazepine-2,5-diones are an important class of biologically actives compounds. 20 This class of compounds has been identified as having platelet aggregation inhibitor activity, anticonvulsant activity, anxiolytic activity and activity as anti tumor agents (Mc Dowell, R.S. et al., J. Am. Chem. Soc., 1994, 116, 5077; Cho, N.S. et al., J Heterocycl. Chem., 1989, 26, 1807; Wright, W.B. et al., J. Med. Chem., 1978, 21, 1087; Jones; G.B. et al., Anti-Cancer Drug Des. 1990, 5, 249).

25 Diketopiperazines are known to be ligands of neurokinin-2 receptors and neurokinin-3 receptors (Gordon, D.W.; Steele, J. Bioorg. Med. Chem. Lett., 1995, 5, 47. (b) Terrett, N.K.; Gardner, M.; Gordon, D.W.; Kobylecki, R.J.; Steele, J., Tetrahedron, 1995, 51, 8135) and are useful in the treatment of asthma, inflammation, Parkinsons disease, anxiety, psychosis, epilepsy and pain.

30 Reports of the biological utility of ketopiperazines have appeared in several areas, including applications as antagonists of the platelet glycoprotein IIb-IIIa (Takada, S.; Kurokawa, T.; Miyazaki, K.; Iwasa, S.; Ogawa, Y. Pharm. Res. 1997, 14, 1146), and substance P (Wright, H. B.; Martin, D. L. J. Med. Chem.. 1968, 11, 390) and as hypocholesteremic agents (Piercey, M. F.; Moon, M. W.; Blinn, J. R. Brain Res., 1986, 385, 74).

35 Reports of the biological utility of dihydroquinoxalinones (also known as benzopiperazinones) have appeared in several areas, including applications as inhibitors of aldose reductase (Sarges, R.; Lyga, J.W. J. Heterocycl. Chem. 1988, 25, 1474), and partial agonists of the gamma-aminobutyric acid (GABA)/benzodiazepine receptor complex (Tenbrink,

R.E.; Im, W.B.; Sethy, V.H.; Tang, A.H.; Carter, D.B. *J. Med. Chem.* 1994, 37, 758), angiotensin II receptor antagonists (Kim, K.S.; Qian, L.; Bird, J.E.; Dickinson, K.E.; Moreland, S.; Schaeffer, T.R.; Waldron, T.L.; Delaney, C.L.; Weller, H.N.; Miller, A.V. *J. Med. Chem.* 1993, 36, 2335); also they are known to possess antiviral activity as associated with HIV (Meichsner, C.; Riess, G.; Kleim, J.P.; Roesner, M.; Paessens, A.; Blunck, M. *Eur. Pat. Appl. EP 657166 A1 950614*).

Early work pioneered by Freidinger (Freidinger, R.M.; Perlow, D.S.; Veber, D.F. *J. Org. Chem.* 1982, 47, 104) showed γ -lactams to be a useful new type of conformational constraint in peptides and useful in the synthesis of LHRH (Samenen, J.; Hempel, J.C.; Narindray, D.; Regoli, D. 'Peptides. Chemistry and Biology', *Proc. 10th Am. Peptide Symp.* 1988, 137), angiotensin II (Douglas, A.J.; Mulholland, G.; Walker, B.; Guthrie, D.J.S.; Elmore, D.T.; Murphy, R.F. *Biochem. Soc. Trans.* 1988, 16, 175), pentagastrin (Piercey, M.F.; Moon, M.W.; Blinn, J.R.; Dobry-Schreur, P.J.K. *Brain Res.* 1986, 385, 74), and substance P analogues. The lactams described herein, in particular those produced via cyclization of a primary amine, result in potential ATP competitive kinase inhibitors possessing functionality that may mimic the N1 - N6 interaction of ATP binding to a relevant kinase (Myers, M. R.; He, W.; Hulme, C. *Curr. Pharm. Design.* 1997, 3, 473).

Benzodiazepines have been shown to have utility as GPIIb/IIIa receptor antagonists (Ku, T. W.; Miller, W. H.; Bondinell, W. E.; Erhard, K. F.; Keenan, R. M.; Nichols, A. J.; Peishoff, C. E.; Samenen, J. M.; Wong, A. S.; Huffman, W. F. *J. Med. Chem.* 1995, 38, 9 - 12) and may be useful for the treatment of acute myocardial infarction, unstable angina, or thrombotic stroke. Recent developments have extended the therapeutic utility of this class of molecule to include integrin antagonists (for example antagonists of the vitronectin receptor), useful for the stimulation of bone formation and treatment of bone fractures, osteoporosis and other bone-related disorders (Drake, F.H. WO98115278-A1, 1997).

Dihydroimidazoles (or imidazolines) have been shown to have biological utility as antidepressants and additionally imidazoline receptors are widely distributed in both the peripheral and central nervous system playing potential roles in the regulation of several physiological effects (Pigini, M.; Bousquet, P.; Carotti, A.; Dontenwill, M.; Gianella, M.; Moriconi, R.; Piergentili, A.; Quaglia, W.; Tayebati, S.K.; Brasili, L.; *Bioorg. Med. Chem.* 1997, 5, 833; Harfenist, M.; Heuser, D.J.; Joyner, C.T.; Batchelor, J.F.; White, H.L.; *J. Med. Chem.* 1996, 39, 1857; Jackson, H.C.; Griffin, I.J.; Nutt, D.J.; *Br. J. Pharmacol.* 1991, 104, 258; and Tibirica, E.; Feldman, J.; Mermet, C.; Gonon, F.; Bousquet, P. *J. Pharmacol.* 1987, 134, 1). The imidazoline moiety has also been extensively studied as an amide bond replacement in biologically active peptides (Gilbert, I.; Rees, D.C.; Richardson, R.S. *Tetrahedron Lett.* 1991, 32, 2277; and Jones, R.C.F.; Ward, G.J. *Tetrahedron Lett.* 1988, 29, 3853).


Cyclic ureas have recently shown promise as integrin receptor antagonists useful for the treatment and prevention of bone resorption, restenosis, angiogenesis and diabetic retinopathy (see M.E. Duggan et al., WO9931099-A1 and M.E. Duggan et al., WO9930713-A1).

Also, hydantoins have recently shown promise as inhibitors of leukocyte adhesion and migration and VLA-4 receptor inhibitors useful for the treatment and prevention of e.g. rheumatoid arthritis and inflammatory bowel disease (see V. Wehner et al., EP-903353-A1).


Pressures on the pharmaceutical industry have increased significantly to meet new economic challenges. As a consequence, efforts in both industrial and academic sectors are now being directed at new technologies for approaching drug discovery in a more efficient and cost-effective manner. As such, with the recent development of combinatorial chemistry and high speed parallel synthesis within the Lead Discovery arena, the multi-component reaction (MCR) has witnessed a resurgence of interest. From a practical consideration, "one-pot reactions", such as the Ugi and Passerini reactions, are easily automated, and production of diverse or directed libraries of small organic molecules is thus both facile and high-throughput. Despite this tremendous synthetic potential, the Ugi reaction is limited in that it produces products that are flexible and peptidic-like, often being classified as "non-drug-like" and exhibiting bioavailability problems. Interestingly, several novel intramolecular variations of this versatile reaction have recently been reported, wherein constrained products are achieved by intercepting the intermediate nitrilium ion of the Ugi reaction. An alternative approach, and the one described in this application, is to constrain the Ugi product via a so-called secondary reaction after initial formation of the classical Ugi product. Production of the derivatives described herein is facile and amenable to automated high throughput production, allowing production of vast arrays of biologically relevant molecules (in the range of at least 10,000 molecules/template, revealed in good purity).

Summary of the Invention

The present invention relates to a method for preparing an N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound of the formula




wherein



R_{aa} is hydrogen, alkoxy, an optionally substituted aliphatic moiety or an optionally substituted aromatic moiety;

- 5 R_b is hydrogen, an optionally substituted aliphatic moiety or an optionally substituted aromatic moiety;

R_{ca} and R_{cb} are independently hydrogen, optionally substituted aliphatic or optionally substituted aromatic;



- 10 R_d is ; and

R_{da} is optionally substituted aliphatic or optionally substituted aromatic; and wherein either R_{aa} is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with the *ab or *db carbon, or with at least one R_b , R_{ca} and R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring; or

- 15 R_b is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with the *ab or *db carbon, or with at least one R_{aa} , R_{ca} and R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring; or


- 20 at least one of R_{ca} and R_{cb} is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with the *ab or *db carbon, or with at least one R_{aa} , R_b , R_{ca} , R_{cb} and R_{da} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring; or

- 25 R_{da} is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with at least one of R_{ca} and R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring,

provided that, when R_{aa} is substituted with a primary or secondary protected amine that, upon deprotection, can react with R_b (substituted with an activated carboxylic acid), then R_{aa} is substituted aromatic,

- 30 this method comprising reacting:

(i) a carbonyl compound of formula



- (ii) an amine compound of formula
 5 NH_2R_b ,
 (iii) an isonitrile compound of formula
 NCR_{da} , and
 (iv) an acid compound of formula
 R_aCO_2H ,
 10 to produce the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound. The invention
 is also directed to a method for cyclizing an N-[(aliphatic or aromatic)carbonyl]-2-
 aminoacetamide compound to a cyclic compound selected from the group consisting of a 1,4-
 benzodiazepine-2,5-dione derivatives, diketopiperazine derivatives, ketopiperazine derivatives,
 lactam derivatives, 1,4-benzodiazapine derivatives and dihydroquinoxalinones derivative, cyclic
 15 ureas, hydantoins, as well as to the cyclized compound per se.

DETAILED DESCRIPTION

- As used above, and throughout the description of the invention, the following terms,
 20 unless otherwise indicated, shall be understood to have the following meanings:-
 "Acid bioisostere" means a group which has chemical and physical similarities producing
 broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in
 Medicinal Chemistry, 1986, 21, p.283 "Bioisosterism In Drug Design"; Yun, Hwahak Sekye,
 1993, 33, p.576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue
 25 Tongbao, 1995, p.34-38 "Bioisosteric Replacement And Development Of Lead Compounds In
 Drug Design"; Graham, Theochem, 1995, 343, p.105-109 "Theoretical Studies Applied To Drug
 Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid
 bioisosteres include: $-C(=O)-NHOH$, $-C(=O)-CH_2OH$, $-C(=O)-CH_2SH$, $-C(=O)-NH-CN$, sulpho,
 phosphono, alkylsulphonylcarbamoyl, tetrazolyl, arylsulphonylcarbamoyl,
 30 heteroarylsulphonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-
 dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and
 3-hydroxy-1-methylpyrazolyl.
 "Acidic functional group" means a group with an acidic hydrogen within it. The
 "corresponding protected derivatives" are those where the acidic hydrogen atom has been
 35 replaced with a suitable protecting group, to block or protect the acid functionality while

reactions involving other functional sites of the compound are carried out. Such protecting groups are well known to those skilled in the art, having been extensively used in the protection of carboxyl groups in the penicillin and cephalosporin fields, as described in U.S. Patent No. 3,840,556 and U.S. Patent No. 3,719,667, the disclosures of which are hereby incorporated
5 herein by reference. For reference to suitable protecting groups, see T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991. Exemplary acidic functional groups include carboxyl (and acid bioisosteres), hydroxy, mercapto and imidazole. Examples of carboxylic acid protecting groups include esters, such as methoxymethyl, methylthiomethyl, tetrahydropyranyl, substituted and unsubstituted phenacyl, 2,2,2-
10 trichloroethyl, *tert*-butyl, cinnamyl, dialkylaminoalkyl (e.g., dimethylaminoethyl and the like), trimethylsilyl, and the like, and amides and hydrazides including N,N-dimethyl, 7-nitroindolyl hydrazide, N-phenylhydrazide, C₁ to C₈ loweralkyl (e.g., methyl, ethyl or tertiary butyl and the like); substituted derivatives such as alkoxybenzyl or nitrobenzyl groups and the like; alkanoyloxyalkyl groups such as pivaloyloxymethyl or propionyloxymethyl and the like;
15 aroyloxyalkyl, such as benzoyloxyethyl and the like; alkoxycarbonylalkyl, such as methoxycarbonylmethyl, cyclohexyloxycarbonylmethyl and the like; alkoxycarbonyloxyalkyl, such as *t*-butyloxycarbonyloxymethyl and the like; alkoxycarbonylaminoalkyl, such as *t*-butyloxycarbonylaminomethyl and the like; alkylaminocarbonylaminoalkyl, such as methylaminocarbonylaminomethyl and the like; alkanoylaminoalkyl, such as acetylaminomethyl
20 and the like; heterocycliccarbonyloxyalkyl, such as 4-methylpiperazinylcarbonyloxymethyl and the like; dialkylaminocarbonylalkyl, such as dimethylaminocarbonylmethyl and the like; (5-(loweralkyl)-2-oxo-1,3-dioxolen-4-yl)alkyl, such as (5-*t*-butyl-2-oxo-1,3-dioxolen-4-yl)methyl and the like; and (5-phenyl-2-oxo-1,3-dioxolen-4-yl)alkyl, such as (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl and the like.

25 "Acyl" means an H-CO- or alkyl-CO- group wherein the alkyl group is as herein described. Preferred acyls contain a lower alkyl. Exemplary acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, *t*-butylacetyl, butanoyl and palmitoyl.

"Aliphatic" means a radical derived from a non aromatic C-H bond by removal of the hydrogen atom. The aliphatic radical may be further substituted by additional aliphatic or
30 aromatic radicals as defined herein. Representative aliphatic groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aralkenyl, aralkyloxyalkyl, aralkyloxycarbonylalkyl, aralkyl, aralkynyl, aralkyloxyalkenyl, heteroaralkenyl, heteroaralkyl, heteroaralkyloxyalkenyl, heteroaralkyloxyalkyl, heteroaralkynyl, fused arylcycloalkyl, fused heteroaryl cycloalkyl, fused arylcycloalkenyl, fused heteroaryl cycloalkenyl, fused
35 arylheterocyclyl, fused heteroaryl heterocyclyl, fused arylheterocyclenyl, fused heteroaryl heterocyclenyl, and the like. "Aliphatic", as used herein, also encompasses the residual, non-carboxyl portion of natural and unnatural amino acids as defined herein. Preferred aliphatic contain from about 1 to about 20 carbon atoms.

"Aromatic" means a radical derived from an aromatic C-H bond by removal of the hydrogen atom. Aromatic includes both aryl and heteroaryl rings as defined herein. The aryl or heteroaryl ring may be further substituted by additional aliphatic or aromatic radicals as defined herein. Representative aromatic groups include aryl, fused cycloalkenylaryl, fused
 5 cycloalkylaryl, fused heterocyclaryl, fused heterocyclenylaryl, heteroaryl, fused cycloalkylheteroaryl, fused cycloalkenylheteroaryl, fused heterocyclenylheteroaryl, fused heterocyclylheteroaryl, and the like.

"Acylamino" is an acyl-NH- group wherein acyl is as defined herein.

"Alkenoyl" means an alkenyl-CO- group wherein alkenyl is as defined herein.

10 "Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond, which may be straight or branched-chain, having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; more preferably about 2 to about 5 carbon atoms in the chain. Branched means that one or more lower alkyl groups, such as methyl, ethyl or propyl are attached to a linear alkenyl chain. "Lower alkenyl"
 15 means about 2 to about 4 carbon atoms in the chain, which may be straight or branched. The alkenyl group may be substituted with one or more "alkenyl group substituents" which may be the same or different, and include halo, alkenyloxy, cycloalkyl, cyano, hydroxy, alkoxy, carboxy, alkynyloxy, aralkoxy, aryloxy, aryloxycarbonyl, alkylthio, heteroaralkyloxy, heterocyclyl, heterocyclylalkyloxy, alkoxycarbonyl, aralkoxycarbonyl, heteroaralkyloxycarbonyl or Y^1Y^2N- ,
 20 Y^1Y^2NCO- or $Y^1Y^2NSO_2-$, wherein Y^1 and Y^2 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or where the substituent is Y^1Y^2N- , then one of Y^1 and Y^2 may be acyl or aroyl as defined herein and the other of Y^1 and Y^2 is as defined previously, or where the substituent is Y^1Y^2NCO- or $Y^1Y^2NSO_2-$, Y^1 and Y^2 may also, taken together with the N atom through which Y^1 and Y^2 are linked, form a 4 to 7 membered heterocyclyl or heterocyclenyl group. Exemplary
 25 alkyl groups include methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *n*-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbonyl, benzyloxycarbonylmethyl, and pyridylmethyloxycarbonylmethyl. Exemplary alkenyl groups include ethenyl, propenyl, *n*-butenyl, *i*-butenyl, 3-methylbut-2-enyl, *n*-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.

30 "Alkenyloxy" means an alkenyl-O- group wherein the alkenyl group is as herein described. Exemplary alkenyloxy groups include allyloxy and 3-butenyloxy.

"Alkenyloxyalkyl" means an alkenyl-O-alkyl group wherein the alkyl and alkenyl groups are as described herein.

"Alkoxy" means an alkyl-O- group wherein the alkyl group is as herein described.

35 Exemplary alkoxy groups include methoxy, ethoxy, *n*-propoxy, *i*-propoxy, *n*-butoxy and heptoxy.

"Alkoxyalkyl" means an alkyl-O-alkyl- group wherein the alkyl groups are independently as herein described. Exemplary alkoxyalkyl groups include methoxyethyl, ethoxymethyl, *n*-butoxymethyl and cyclopentylmethyloxyethyl.

"Aminoiminomethyl" means a $\text{NH}_2\text{C}(=\text{NH})$ - group. It is known that this moiety may be mono or di-protected to afford, for example (alkoxycarbonylamino)iminomethyl and (alkoxycarbonylamino)alkoxycarbonyliminomethyl groups.

5 "Alkoxycarbonyl" means an alkyl-O-CO- group, wherein the alkyl group is as herein defined. Exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, and t-butylloxycarbonyl.

"Alkoxycarbonylalkyl" means an alkyl-O-OC-alkyl- group wherein the alkyl groups are independently as herein defined. Preferred alkoxycarbonylalkyl groups include methoxy- and ethoxy-carbonylmethyl as well as methoxy- and ethoxy-carbonyl ethyl.

10 "Alkyl" means an aliphatic hydrocarbon group, which may be straight or branched-chain, having about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups have 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. "Lower alkyl" means that there are about 1 to about 4 carbon atoms in the chain, which may be straight or branched. The alkyl may be
 15 substituted with one or more "alkyl group substituents", which may be the same or different, and include halo, alkenyloxy, cycloalkyl, aroyl, cyano, hydroxy, alkoxy, carboxy, alkynyloxy, aralkoxy, aryloxy, aryloxycarbonyl, alkylthio, heteroarylthio, aralkylthio, arylsulphonyl, alkylsulphonyl, alkylphosphonate, guanidino, heteroaralkyloxy, heterocyclyl, fused heteroarylcyaloalkenyl, fused heteroarylcyaloalkyl, fused heteroarylheterocyclenyl, fused
 20 heteroarylheterocyclyl, fused arylcyaloalkenyl, fused arylcyaloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, alkoxycarbonyl, aralkoxycarbonyl, (alkoxycarbonylamino)iminomethyl, (alkoxycarbonylamino)alkoxycarbonyliminomethyl, heteroaralkyloxycarbonyl, or $\text{Y}^1\text{Y}^2\text{N}$ -, $\text{Y}^1\text{Y}^2\text{NCO}$ - or $\text{Y}^1\text{Y}^2\text{NSO}_2$ -, wherein Y^1 and Y^2 are independently hydrogen, alkyl, aryl, heteroaroyl, aralkyl or heteroaralkyl, or when the substituent is $\text{Y}^1\text{Y}^2\text{NCO}$ - or $\text{Y}^1\text{Y}^2\text{NSO}_2$, Y^1
 25 and Y^2 may also, together with the N atom through which Y^1 and Y^2 are linked, form a 4 to 7 membered heterocyclyl or heterocyclenyl ring. Exemplary alkyl groups include methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *n*-pentyl, *n*-nonyl, decyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbonylethyl, benzyloxycarbonylmethyl, and pyridylmethyloxycarbonylmethyl. Preferred alkyl group
 30 substituents are fused arylcyaloalkenyl, cyano, fused arylcyaloalkyl, aralkylthio, $\text{Y}^1\text{Y}^2\text{N}$ -, $\text{Y}^1\text{Y}^2\text{NCO}$ -, fused arylheterocyclenyl, fused arylheterocyclyl, hydroxy, heterocyclyl, aralkoxy, alkoxycarbonyl, alkylthio, aryloxy, aroyl, heteroaroyl, arylsulphonyl, heteroarylthio alkylphosphonate, alkylsulphonyl, (alkoxycarbonylamino)iminomethyl, (alkoxycarbonylamino)alkoxycarbonyliminomethyl, and cycloalkyl.

35 "Alkylcarbonyl" is an alkyl-NH-CO- group wherein the alkyl group is herein defined.

"Alkylphosphonate" means an $(\text{alkylO})_2\text{P}=\text{O}$ - group wherein the alkyl groups are independently as herein defined.

"Alkylsulfinyl" means an alkyl-SO- group wherein the alkyl group is as defined herein. Preferred alkylsulfinyl groups are those wherein the alkyl group is lower alkyl.

"Alkylsulfonyl" means an alkyl-SO₂- group wherein the alkyl group is as defined herein. Preferred alkylsulfonyl groups are those wherein the alkyl group is lower alkyl.

5 "Alkylsulphonylcarbamoyl" means an alkyl-SO₂-NH-C(=O)- group wherein the alkyl group is as herein described. Preferred alkylsulphonylcarbamoyl groups are those wherein the alkyl group is C₁₋₄ alkyl.

"Alkylthio" means an alkyl-S- group wherein the alkyl group is as herein described. Exemplary alkylthio groups include methylthio, ethylthio, *i*-propylthio and heptylthio.

10 "Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond, which may be straight or branched-chain, having about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and, more preferably, about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups, such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl"

15 means 2 to about 4 carbon atoms in the chain, which may be straight or branched-chain. The alkynyl group may be substituted with one or more "alkynyl group substituents", which may be the same or different, and include halo, alkenyloxy, cycloalkyl, cyano, hydroxy, alkoxy, carboxy, alkynyloxy, aralkoxy, aryloxy, aryloxycarbonyl, alkylthio, heteroaralkyloxy, heterocyclyl, heterocyclylalkyloxy, alkoxycarbonyl, aralkoxycarbonyl, heteroaralkyloxycarbonyl or Y¹Y²N-,

20 Y¹Y²NCO- or Y¹Y²NSO₂-, wherein Y¹ and Y² are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or when the substituent is Y¹Y²N-, then one of Y¹ and Y² may be acyl or aroyl as defined herein and the other of Y¹ and Y² is as defined previously, or when the substituent is Y¹Y²NCO- or Y¹Y²NSO₂, Y¹ and Y² may also, taken together with the N atom through which Y¹ and Y² are linked, form a 4 to 7 membered heterocyclyl or heterocyclenyl ring. Exemplary

25 alkyl groups include methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *n*-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbonyl, benzoyloxycarbonylmethyl, pyridylmethyloxycarbonylmethyl. Exemplary alkynyl groups include ethynyl, propynyl, *n*-butynyl, 2-butynyl, 3-methylbutynyl, *n*-pentynyl, heptynyl, octynyl and decynyl.

30 "Alkynyloxy" means an alkynyl-O- group wherein the alkynyl group is as herein described. Exemplary alkynyloxy groups include propynyloxy and 3-butyloxy.

"Amino acid" means an amino acid selected from the group consisting of natural and unnatural amino acids as defined herein. Preferred amino acids are those possessing an α-amino group. The amino acids may be neutral, positive or negative depending on the substituents in the

35 side chain. "Neutral amino acid" means an amino acid containing uncharged side chain substituents. Exemplary neutral amino acids include alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine and cysteine. "Positive amino acid" means an amino acid in which the side chain substituents are positively charged at

physiological pH. Exemplary positive amino acids include lysine, arginine and histidine.

"Negative amino acid" means an amino acid in which the side chain substituents bear a net negative charge at physiological pH. Exemplary negative amino acids include aspartic acid and glutamic acid. Preferred amino acids are α -amino acids. Exemplary natural amino acids are
5 isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, lysine, arginine, histidine, aspartic acid and glutamic acid.

"Unnatural amino acid" means an amino acid for which there is no nucleic acid codon. Examples of unnatural amino acids include, for example, the D-isomers of the natural α -amino acids as indicated above; Aib (aminobutyric acid), β Aib (3-aminoisobutyric acid), Nva
10 (norvaline), β -Ala, Aad (2-aminoadipic acid), β Aad (3-aminoadipic acid), Abu (2-aminobutyric acid), Gaba (γ -aminobutyric acid), Acp (6-aminocaproic acid), Dbu (2,4-diaminobutyric acid), α -aminopimelic acid, TMSA (trimethylsilyl-Ala), alle (allo-isoleucine), Nle (norleucine), *tert*-Leu, Cit (citrulline), Orn, Dpm (2,2'-diaminopimelic acid), Dpr (2,3-diaminopropionic acid), α - or β -Nal, Cha (cyclohexyl-Ala), hydroxyproline, Sar (sarcosine), and the like; cyclic amino acids; N-
15 α -alkylated amino acids such as MeGly (N- α -methylglycine), EtGly (N- α -ethylglycine) and EtAsn (N- α -ethylasparagine); and amino acids in which the α -carbon bears two side-chain substituents. The names of natural and unnatural amino acids and residues thereof used herein follow the naming conventions suggested by the IUPAC Commission on the Nomenclature of Organic Chemistry and the IUPAC-IUB Commission on Biochemical Nomenclature as set out in
20 "Nomenclature of α -Amino Acids (Recommendations, 1974) " Biochemistry, 14(2), (1975). To the extent that the names and abbreviations of amino acids and residues thereof employed in this specification and appended claims differ from those noted, differing names and abbreviations will be made clear.

"Amino acid side chains" means the substituent found on the carbon between the amino
25 and carboxy groups in α -amino acids. For examples of "corresponding protected derivatives" of amino acid side chains, see T.W. Green and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

"Amine protecting group" means an easily removable group which is known in the art to protect an amino group against undesirable reaction during synthetic procedures and to be
30 selectively removable. The use of amine protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure, and many such protecting groups are known. See, for example, T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991), the contents of which are hereby incorporated herein by reference. Preferred amine protecting groups are acyl, including
35 formyl, acetyl, chloroacetyl, trichloroacetyl, o-nitrophenylacetyl, o-nitrophenoxyacetyl, trifluoroacetyl, acetoacetyl, 4-chlorobutyryl, isobutyryl, o-nitrocinnamoyl, picolinoyl, acylisothiocyanate, aminocaproyl, benzoyl and the like, and acyloxy including methoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 2-trimethylsilylethoxycarbonyl,

vinylloxycarbonyl, allyloxycarbonyl, *t*-butyloxycarbonyl (BOC), 1,1-dimethylpropynyloxycarbonyl, benzyloxycarbonyl (CBZ), *p*-nitrobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, and the like.

5 "Acid labile amine protecting group" means an amine protecting group as defined above which is readily removed by treatment with acid while remaining relatively stable to other reagents. Preferred acid labile amine protecting groups include *tert*-butoxycarbonyl (BOC), and 2-(4-biphenyl)-isopropoxy carbonyl.

10 "Base labile amine protecting group" means an amine protecting group as defined above which is readily removed by treatment with base while remaining relatively stable to other reagents. Preferred base labile amine protecting groups include 9-fluorenylmethoxycarbonyl (FMOC).

15 "Hydrogenation labile amine protecting group" means an amine protecting group as defined above which is readily removed by hydrogenation while remaining relatively stable to other reagents. A preferred hydrogenation labile amine protecting group is benzyloxycarbonyl (CBZ).

"Hydrogenation labile acid protecting group" means an acid protecting group as defined above which is readily removed by hydrogenation while remaining relatively stable to other reagents. A preferred hydrogenation labile acid protecting group is benzyl.

20 "Analogue" means a compound which comprises a chemically modified form of a specific compound or class thereof, and which maintains the pharmaceutical and/or pharmacological activities characteristic of said compound or class.

"Aralkenyl" means an aryl-alkenyl- group wherein the aryl and alkenyl are as herein described. Preferred aralkenyl groups contain a lower alkenyl moiety. An exemplary aralkenyl group is 2-phenethenyl.

25 "Aralkoxy" means an aralkyl-O- group wherein the aralkyl group is as herein described. Exemplary aralkoxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.

"Aralkoxyalkyl" means an aralkyl-O-alkyl group wherein the aralkyl and alkyl groups are as herein described. An exemplary aralkoxyalkyl group is benzyloxyethyl.

30 "Aralkoxycarbonyl" means an aralkyl-O-CO- group wherein the aralkyl groups is as herein described. An exemplary aralkoxycarbonyl group is benzyloxycarbonyl.

"Aralkoxycarbonylalkyl" means an aralkyl-OOC-alkyl- group wherein the alkyl and aralkyl groups are as herein described. Preferred aralkoxycarbonylalkyl groups include benzyloxy-carbonyl methyl and benzyloxy-carbonyl ethyl.

35 "Aralkyl" means an alkyl group substituted by one or more aryl groups, wherein the aryl and alkyl are as herein described. Preferred aralkyl groups contain a lower alkyl moiety. Exemplary aralkyl groups include benzyl; 2,2-diphenylethyl; 2,2-diphenylmethyl; 2-phenethyl and naphthalenemethyl.

"Aralkylamino" means an aryl-alkyl-NH- group wherein aryl and alkyl are as defined herein. Exemplary aralkylamino groups include phenethylamino.

"Aralkyloxyalkenyl" means an aralkyl-O-alkenyl group wherein the aralkyl and alkenyl groups are as herein described. An exemplary aralkyloxyalkenyl group is 3-benzyloxyallyl.

5 "Aralkylsulfonyl" means an aralkyl-SO₂- group wherein the aralkyl group is as herein described. Exemplary aralkylsulfonyl groups include phenethylsulfonyl.

"Aralkylsulfinyl" means an aralkyl-SO- group wherein the aralkyl group is as herein described. Exemplary aralkylsulfinyl groups include phenethylsulfinyl.

"Aralkylthio" means an aralkyl-S- group wherein the aralkyl group is as herein described.
10 An exemplary aralkylthio group is benzylthio.

"Aroyl" means an aryl-CO- group wherein the aryl group is as herein described. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.

"Aroylamino" is an aroyl-NH- group wherein aroyl is as defined herein. Exemplary aroylamino groups include benzoylamino groups.

15 "Aryl" means an aromatic monocyclic or multicyclic ring system of about 6 to about 14 carbon atoms, preferably of about 6 to about 10 carbon atoms. The aryl is optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Representative aryl groups include phenyl, naphthyl, substituted phenyl and substituted naphthyl groups. Preferred aryl groups are phenyl and naphthyl.

20 "Aralkenyl" means an aryl-alkenyl- group wherein the aryl and alkenyl moieties are as described herein. Preferred aralkenyl groups contain a C₂₋₁₂ alkenyl moiety. Exemplary aralkenyl groups include styryl; 4-phenyl-1,3-pentadienyl; and 2,5-dimethyl-2-phenyl-4-hexenyl,

"Aralkynyl" means an aryl-alkynyl- group wherein the aryl and alkynyl
25 moieties are as described herein. Exemplary aralkynyl groups include phenylacetylenyl and 3-phenylbut-2-ynyl.

"Arylazo" means an aryl-azo- group wherein the aryl and azo groups are as defined herein. Exemplary arylazo compounds include naphthalene-2-azo.

"Arylcarbamoyl" is an aryl-NHCO- group, wherein the aryl group is as defined herein.
30 Exemplary arylcarbamoyl compounds include benzaryl.

"Fused arylcycloalkenyl" means a fused aryl and cycloalkenyl wherein the aryl and cycloalkenyl groups are as defined herein. Preferred fused arylcycloalkenyl groups are those wherein the aryl thereof is phenyl and the cycloalkenyl consists of about 5 to 6 ring atoms. A fused arylcycloalkenyl group may be bonded through any atom of the ring system thereof capable
35 of such bonding. The fused arylcycloalkenyl group may be optionally substituted by one or more ring system substituents, wherein the "ring system substituent" is as defined herein. Representative fused arylcycloalkenyl groups include 1,2-dihydronaphthylene, indene, and the like.

"Fused arylcycloalkyl" means a fused aryl and cycloalkyl wherein the aryl and cycloalkyl groups are as defined herein. Preferred fused arylcycloalkyl groups are those wherein the aryl thereof is phenyl and the cycloalkyl consists of about 5 to 6 ring atoms. A fused arylcycloalkyl group may be bonded through any atom of the ring system thereof capable of such bonding. The fused arylcycloalkyl group may be optionally substituted by one or more ring system substituents, wherein the "ring system substituent" is as defined herein. Representative fused arylcycloalkyl groups includes 1,2,3,4-tetrahydronaphthyl; 5,6,7,8-tetrahydronaphth-1-yl, and the like.

"Fused arylheterocyclenyl" means a fused aryl and heterocyclenyl wherein the aryl and heterocyclenyl groups are as defined herein. Preferred fused arylheterocyclenyl groups are those wherein the aryl thereof is phenyl and the heterocyclenyl consists of about 5 to 6 ring atoms. A fused arylheterocyclenyl group may be bonded through any atom of the ring system thereof capable of such bonding. The designation of aza, oxa or thia as a prefix before heterocyclenyl portion of the fused arylheterocyclenyl means that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The fused arylheterocyclenyl group may be optionally substituted by one or more ring system substituent, wherein the "ring system substituent" is as defined herein. The nitrogen atom of a fused arylheterocyclenyl group may be a basic nitrogen atom. The nitrogen or sulphur atom of the heterocyclenyl portion of the fused arylheterocyclenyl group may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Representative fused arylheterocyclenyl groups include 3H-indoliny; 1H-2-oxoquinolyl; 2H-1-oxoisoquinolyl; 1,2-dihydroquinoliny; 3,4-dihydroquinoliny; indazolyl; 1,2-dihydroisoquinoliny; benzotriazolyl; 3,4-dihydroisoquinoliny, and the like.

"Fused arylheterocyclyl" means a fused aryl and heterocyclyl wherein the aryl and heterocyclyl groups are as defined herein. Preferred fused arylheterocyclyl groups are those wherein the aryl thereof is phenyl and the heterocyclyl consists of about 5 to 6 ring atoms. A fused arylheterocyclyl group may be bonded through any atom of the ring system thereof capable of such bonding. The designation of aza, oxa or thia as a prefix before heterocyclyl portion of the fused arylheterocyclyl means that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The fused arylheterocyclyl group may be optionally substituted by one or more ring system substituent, wherein the "ring system substituent" is as defined herein. The nitrogen atom of a fused arylheteroaryl group may be a basic nitrogen atom. The nitrogen or sulphur atom of the heterocyclyl portion of the fused arylheterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Representative preferred fused arylheterocycl ring systems include indoliny, phthalimide; 1,2,3,4-tetrahydroisoquinoline; 1,2,3,4-tetrahydroquinoline 1H-2,3-dihydroisoindol-2-yl; 2,3-dihydrobenz[f]isoindol-2-yl; 1,2,3,4-tetrahydrobenz[g]isoquinolin-2-yl; 1,3-benzodioxole, and the like.

"Aryloxy" means an aryl-O- group wherein the aryl group is as defined herein. Exemplary aryloxy groups include phenoxy and 2-naphthyloxy.

"Aryloxyalkyl" means an aryl-O-alkyl- group wherein the aryl and alkyl groups are as herein described. An exemplary aryloxyalkyl group is phenoxypropyl.

"Aryloxyalkenyl" means an aryl-O-alkenyl- group wherein the aryl and alkenyl groups are as herein described. An exemplary aryloxyalkenyl group is phenoxyallyl.

5 "Aryloxycarbonyl" means an aryl-O-CO- group wherein the aryl group is as defined herein. Exemplary aryloxycarbonyl groups include phenoxy carbonyl and naphthoxy carbonyl.

"Aryloxycarbonylalkyl" means an aryl-O-OC-alkyl- group. Preferred groups include phenoxy carbonyl- methyl and phenoxy carbonyl -ethyl.

"Arylsulfonyl" means an aryl-SO₂- group wherein the aryl group is as defined herein.

10 "Arylsulfinyl" means an aryl-SO- group wherein the aryl group is as defined herein.

"Arylthio" means an aryl-S- group wherein the aryl group is as herein described. Exemplary arylthio groups include phenylthio and naphthylthio.

15 "Basic nitrogen atom" means an sp² or sp³ hybridized nitrogen atom having a non-bonded pair of electrons which is capable of being protonated. Examples of groups that contain basic nitrogen atoms include optionally substituted imino, optionally substituted amino and optionally substituted amidino groups.

"Carbamoyl" is an NH₂-CO- group.

"Carboxy" means an HO(O)C- (carboxylic acid) group.

20 "Carboxyalkyl" means an HOOC-alkyl- group wherein the alkyl group is as defined herein. Preferred carboxyalkyl groups include carboxymethyl and carboxyethyl.

"Compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (I), and compounds of formula (II), as hereinbefore described, and to include their prodrugs, their pharmaceutically acceptable salts, and their solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they
25 themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and their use is not intended to exclude other instances when the context so permits.

30 "Cycloalkoxy" means an cycloalkyl-O- group wherein the cycloalkyl group is as herein described. Exemplary cycloalkoxy groups include cyclopentyloxy and cyclohexyloxy.

"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system of about 3 to about 10 carbon atoms. Preferred ring sizes of rings of the ring system include about 5 to 6 ring atoms. The cycloalkyl group is optionally substituted with one or more "ring system substituents", which may be the same or different, and are as defined herein. Representative monocyclic
35 cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. Representative multicyclic cycloalkyl groups include 1-decalin, norbornyl,

adamant-(1- or 2-)yl, 6,6-dimethylbicyclo[3.1.1]heptane, and the like. Preferred ring system substituents for a cycloalkyl include alkyl, aralkoxy, amidino, hydroxy, and Y^1Y^2N - as defined herein.

5 "Cycloalkylcarbonyl" means a cycloalkyl-CO- group, wherein the cycloalkyl group is as hereinbefore defined. Exemplary cycloalkylcarbonyl groups include cyclopropylcarbonyl, and the like.

10 "Cycloalkenyl" means a non-aromatic mono- or multicyclic ring system of about 3 to about 10 carbon atoms, preferably of about 5 to about 10 carbon atoms, which contains at least one carbon-carbon double bond. Preferred ring sizes of rings of the ring system include about 5 to 6 ring atoms. The cycloalkenyl is optionally substituted with one or more "ring system substituents", which may be the same or different, and are as defined herein. Representative monocyclic cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like. A representative multicyclic cycloalkenyl group is norbornenyl. Preferred ring system substituents for a cycloalkyl group are amidino and Y^1Y^2N - as defined herein

15 "Derivative" means a chemically modified compound wherein the modification is considered routine by the ordinary skilled chemist, such as an ester or an amide of an acid, protecting groups, such as a benzyl group for an alcohol or thiol, and tert-butoxycarbonyl group for an amine.

"Azo" means a bivalent $-N=N-$ radical.

20 "Effective amount" means an amount of a compound/composition according to the present invention effective in producing the desired therapeutic effect.

"Electron donating group" means a group that will release or donate electrons more than hydrogen would if it occupied the same position in the molecule. See J. March, Advanced Organic Chemistry, 3rd Ed., John Wiley & Sons p. 238 (1985). These types of groups are well known in the art. Examples include alkyl, aralkyl, cycloalkyl, heteroaralkyl, heteroaryl, or heterocyclyl.

30 "Formulations suitable for nasal or inhalational administration" means formulations which are in a form suitable to be administered nasally or by inhalation to a patient. The formulation may contain a carrier, in a powder form, having a particle size, for example, in the range 1 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.) Suitable formulations wherein the carrier is a liquid, for administration as, for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents. Inhalational therapy is readily administered by metered dose inhalers.

35 "Formulations suitable for oral administration" means formulations which are in a form suitable to be administered orally to a patient. The formulations may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active

ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

5 “Formulations suitable for parenteral administration” means formulations which are in a form suitable to be administered parenterally to a patient. The formulations are sterile and include emulsions, suspensions, aqueous and non-aqueous injection solutions, which may contain suspending agents, thickening agents, anti-oxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient and have a suitably adjusted pH.


10 “Formulations suitable for rectal administrations” means formulations which are in a form suitable to be administered rectally to a patient. The formulation is preferably in the form of suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and, therefore, melt
15 in the rectum and release the active component.

 “Formulations suitable for systemic administration” means formulations which are in a form suitable to be administered systemically to a patient. The formulation is preferably administered by injection, including transmuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds of the invention are formulated in liquid solutions,
20 preferably in physiologically compatible buffers such as Hank’s solution or Ringer’s solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included. Systemic administration also can be by transmucosal or transdermal means, or the compounds can be administered orally. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated
25 are used in the formulation. Such penetrants are generally known in the art, and include, for example, bile salts and fusidic acid derivatives for transmucosal administration. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through use of nasal sprays, for example, or suppositories. For oral administration, the compounds are formulated into conventional oral administration forms such as capsules, tablets, and tonics.

30 “Formulations suitable for topical administration” means formulations which are in a form suitable to be administered to a patient. The formulation may be presented as a topical ointment, salve, powder, spray and inhalant, gel (water or alcohol based), creams, as is generally known in the art, or incorporated into a matrix base for application in a patch, which would allow a controlled release of compound through the dermal barrier. When formulated in an ointment,
35 the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. Formulations suitable for topical administration in the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an

aqueous solvent for the active ingredient. Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

"Formulations suitable for vaginal administration" means formulations which are in a form suitable to be administered vaginally to a patient. The formulation may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.



"Guanidino" or "guanidine" means a group of formula

"Halo" means fluoro, chloro, bromo, or iodo. Preferred halo are fluoro, chloro or bromo, and more preferred are fluoro or chloro.

"Heteroaralkenyl" means an heteroaryl-alkenyl- group wherein the heteroaryl and alkenyl moieties are as herein described. Preferred heteroaralkenyl groups contain a lower alkenyl moiety. Exemplary heteroaralkenyl groups are 4-pyridylvinyl, thienylethenyl, pyridylethenyl, imidazolylethenyl and pyrazinylethenyl.

"Heteroaralkyl" means a heteroaryl-alkyl- group wherein the heteroaryl and alkyl moieties are as herein described. Preferred heteroaralkyl groups contain a lower alkyl moiety.

Exemplary heteroaralkyl groups include thienylmethyl, pyridylmethyl, imidazolylmethyl and pyrazinylmethyl.

"Heteroaralkyloxy" means an heteroaralkyl-O- group wherein the heteroaralkyl group is as herein described. An exemplary heteroaralkyloxy group is 4-pyridylmethoxy.

"Heteroaralkyloxyalkenyl" means an heteroaralkyl-O-alkenyl group wherein the heteroaralkyl and alkenyl groups are as herein described. An exemplary heteroaralkyloxyalkenyl group is 4-pyridylmethoxyallyl.

"Heteroaralkyloxyalkyl" means an heteroaralkyl-O-alkyl group wherein the heteroaralkyl and alkyl groups are as herein described. An exemplary heteroaralkyloxy group is 4-pyridylmethoxyethyl.

"Heteroaralkynyl" means an heteroaryl-alkynyl- group wherein the heteroaryl and alkynyl groups are as herein described. Preferred heteroaralkynyl groups contain a lower alkynyl moiety. Exemplary heteroaralkynyl groups are pyrid-3-ylacetylenyl, quinolin-3-ylacetylenyl and 4-pyridylethynyl.

"Heteroaroyl" means an means an heteroaryl-CO- group wherein the heteroaryl group is as herein described. Exemplary heteroaroyl groups include thiophenoyl, nicotinoyl, pyrrol-2-ylcarbonyl and 1- and 2-naphthoyl and pyridinoyl.

"Heteroaryl" means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 carbon atoms, preferably about 5 to about 10 carbon atoms, in which at least one of the atoms in the ring system is an (hetero) element(s) other than carbon, for example nitrogen, oxygen or sulfur. Preferred ring sizes of rings of the ring system include about 5 to 6 ring atoms.

5 The heteroaryl group may also be substituted by one or more "ring system substituents", which may be the same or different, and are as defined herein. The designation of aza, oxa or thia as a prefix before heteroaryl means that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. A nitrogen atom of an heteroaryl may be a basic nitrogen atom and may also be optionally oxidized to the corresponding N-oxide. Representative heteroaryl and
10 substituted heteroaryl groups include pyrazinyl, furanyl, thienyl, pyridyl, pyrimidinyl, isoxazolyl, isothiazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalynyl, phthalazinyl, imidazo[1,2-a]pyridine, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolynyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidinyl, pyrrolopyridyl, imidazopyridyl,
15 isoquinolynyl, benzoazaindole, 1,2,4-triazinyl. Preferred heteroaryl groups include pyrazinyl, thienyl, pyridyl, pyrimidinyl, quinolynyl, tetrazolyl, imidazolyl, thiazolyl, benzothienyl, isoxazolyl and isothiazolyl.

"Heteroarylalkenyl" means a heteroaryl-alkenyl-group wherein the heteroaryl and alkenyl moieties are as described herein. Preferred heteroarylalkenyl groups contain a C₂₋₁₂
20 alkenyl moiety. Exemplary heteroarylalkenyl groups include pyridylpentenyl, pyridylhexenyl and pyridylheptenyl.

"Heteroarylalkynyl" means a heteroaryl-alkynyl- group wherein the heteroaryl and alkynyl moieties are as herein described. Preferred heteroarylalkynyl groups contain a C₂₋₁₂ alkynyl moiety. Exemplary heteroarylalkynyl groups include 3-pyridyl-
25 but-2-ynyl and pyridylpropynyl.

"Heteroarylazo" means an heteroaryl -azo- group wherein the heteroaryl and azo groups are as defined herein.

"Fused heteroarylcyκλοalkenyl" means a fused heteroaryl and cycloalkenyl group wherein the heteroaryl and cycloalkenyl moieties are as defined herein. Preferred fused
30 heteroarylcyκλοalkenyl groups are those wherein the heteroaryl thereof is phenyl and the cycloalkenyl portion consists of about 5 to 6 ring atoms. A fused heteroarylcyκλοalkenyl as a variable may be bonded through any atom of the ring system thereof capable of such. The designation of aza, oxa or thia as a prefix before the heteroaryl portion of the fused heteroarylcyκλοalkenyl means that at least a nitrogen, oxygen or sulfur atom is present
35 respectively as a ring atom. The fused heteroarylcyκλοalkenyl group may be optionally substituted by one or more ring system substituents, wherein the "ring system substituent" is as defined herein. The nitrogen atom of a fused heteroarylcyκλοalkenyl group may be a basic nitrogen atom. The nitrogen atom of the heteroaryl portion of the fused heteroarylcyκλοalkenyl

group may also be optionally oxidized to the corresponding N-oxide. Representative fused heteroarylcycloalkenyl groups include 5,6-dihydroquinolyl; 5,6-dihydroisoquinolyl; 5,6-dihydroquinoxalyl; 5,6-dihydroquinazolyl; 4,5-dihydro-1H-benzimidazolyl; 4,5-dihydrobenzoxazolyl, and the like.

5 “Fused heteroarylcycloalkyl” means a fused heteroaryl and cycloalkyl group wherein the heteroaryl and cycloalkyl moieties are as defined herein. Preferred fused heteroarylcycloalkyl groups are those wherein the heteroaryl portion thereof consists of about 5 to 6 ring atoms and the cycloalkyl consists of about 5 to about 6 ring atoms. A fused heteroarylcycloalkyl group may be bonded through any atom of the ring system thereof capable of such. The designation of aza,
10 oxa or thia as a prefix before the heteroaryl portion of the fused heteroarylcycloalkyl group means that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The fused heteroarylcycloalkyl group may be optionally substituted by one or more ring system substituents, wherein the “ring system substituent” is as defined herein. The nitrogen atom of a fused heteroarylcycloalkyl group may be a basic nitrogen atom. The nitrogen atom of the
15 heteroaryl portion of the fused heteroarylcycloalkyl group may also be optionally oxidized to the corresponding N-oxide. Representative fused heteroarylcycloalkyl groups include 5,6,7,8-tetrahydroquinolyl; 5,6,7,8-tetrahydroisoquinolyl; 5,6,7,8-tetrahydroquinoxalyl; 5,6,7,8-tetrahydroquinazolyl; 4,5,6,7-tetrahydro-1H-benzimidazolyl; 4,5,6,7-tetrahydrobenzoxazolyl; 1H-4-oxa-1,5-diazanaphthalen-2-onyl; 1,3-dihydroimidazole-[4,5]-pyridin-2-onyl, and the like.

20 “Fused heteroarylheterocyclenyl” means a fused heteroaryl and heterocyclenyl group wherein the heteroaryl and heterocyclenyl moieties are as defined herein. Preferred fused heteroarylheterocyclenyl groups are those wherein the heteroaryl portion thereof consists of about 5 to 6 ring atoms and the heterocyclenyl portion consists of about 5 to 6 ring atoms. A fused heteroarylheterocyclenyl group may be bonded through any atom of the ring system thereof
25 capable of such. The designation of aza, oxa or thia as a prefix before the heteroaryl or heterocyclenyl portion of the fused heteroarylheterocyclenyl group means that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The fused heteroarylheterocyclenyl group may be optionally substituted by one or more ring system substituents, wherein the “ring system substituent” is as defined herein. The nitrogen atom of a
30 fused heteroarylazaheterocyclenyl group may be a basic nitrogen atom. The nitrogen or sulphur atom of the heteroaryl or heterocyclenyl portion of the fused heteroarylheterocyclenyl group may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Representative fused heteroarylheterocyclenyl groups include 7,8-dihydro[1,7]naphthyridinyl; 1,2-dihydro[2,7]naphthyridinyl; 6,7-dihydro-3H-imidazo[4,5-c]pyridyl; 1,2-dihydro-1,5-naphthyridinyl; 1,2-dihydro-1,6-naphthyridinyl; 1,2-dihydro-1,7-naphthyridinyl; 1,2-dihydro-1,8-naphthyridinyl; 1,2-dihydro-2,6-naphthyridinyl, and the like.

35 “Fused heteroarylheterocyclyl” means a fused heteroaryl and heterocyclyl group wherein the heteroaryl and heterocyclyl moieties are as defined herein. Preferred fused

heteroarylheterocyclyl groups are those wherein the heteroaryl portion thereof consists of about 5 to 6 ring atoms and the heterocyclyl portion consists of about 5 to 6 ring atoms. A fused heteroarylheterocyclyl group may be bonded through any atom of the ring system thereof capable of such. The designation of aza, oxa or thia as a prefix before the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl group means that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The fused heteroarylheterocyclyl group may be optionally substituted by one or more ring system substituents, wherein the "ring system substituent" is as defined herein. A nitrogen atom of a fused heteroarylheterocyclyl group may be a basic nitrogen atom. A nitrogen or sulphur atom of the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl group may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Representative fused heteroarylheterocyclyl groups include 2,3-dihydro-1H pyrrol[3,4-b]quinolin-2-yl; 1,2,3,4-tetrahydrobenz [b][1,7]naphthyridin-2-yl; 1,2,3,4-tetrahydrobenz [b][1,6]naphthyridin-2-yl; 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl; 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-2-yl; 2,3-dihydro-1H-pyrrolo[3,4-b]indol-2-yl; 1H-2,3,4,5-tetrahydroazepino[3,4-b]indol-2-yl; 1H-2,3,4,5-tetrahydroazepino[4,3-b]indol-3-yl, 1H-2,3,4,5-tetrahydroazepino[4,5-b]indol-2-yl; 5,6,7,8-tetrahydro[1,7]naphthyridinyl, 1,2,3,4-tetrahydro[2,7]naphthyridinyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridyl; 2,3-dihydro[1,4]dioxino[2,3-b]pyridyl; 3,4-dihydro-2H-1-oxa[4,6]diazanaphthalenyl; 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridyl; 6,7-dihydro[5,8]diazanaphthalenyl; 1,2,3,4-tetrahydro[1,5]naphthyridinyl; 1,2,3,4-tetrahydro[1,6]naphthyridinyl; 1,2,3,4-tetrahydro[1,7]naphthyridinyl; 1,2,3,4-tetrahydro[1,8]naphthyridinyl; 1,2,3,4-tetrahydro[2,6]naphthyridinyl, and the like.

"Heteroarylsulphonylcarbonyl" means a heteroaryl-SO₂-NH-C(=O)- group wherein the heteroaryl group is as herein described.

"Heterocyclenyl" means a non-aromatic monocyclic or multicyclic hydrocarbon ring system of about 3 to about 13 carbon atoms, preferably about 5 to about 13 carbon atoms, in which one or more of the carbon atoms in the ring system is/are replaced by an atom of an element other than carbon (i.e., a "heteroatom"), for example nitrogen, oxygen or sulfur, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. Preferred ring sizes of rings of the ring system include about 5 to 6 ring atoms. The designation of aza, oxa or thia as a prefix before the heterocyclenyl means that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The heterocyclenyl group may be optionally substituted by one or more ring system substituents, wherein the "ring system substituent" is as defined herein. The nitrogen atom of an heterocyclenyl group may be a basic nitrogen atom. A nitrogen or sulphur atom of the heterocyclenyl group may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Representative monocyclic azaheterocyclenyl groups include 1,2,3,4-tetrahydrohydropyridine; 1,2-dihydropyridyl; 1,4-dihydropyridyl; 1,2,3,6-tetrahydrohydropyridine; 1,4,5,6-tetrahydropyrimidine; 2-pyrrolinyl; 3-pyrrolinyl; 2-imidazolyl; 2-pyrazolyl; 1,4,4a,5a,6,9,9a,9b-octahydro-dibenzofuran, and the like.

Exemplary oxaheterocyclenyl groups include 3,4-dihydro-2*H*-pyran, dihydrofuranyl, and fluorodihydrofuranyl. Preferred is dihydrofuranyl. An exemplary multicyclic oxaheterocyclenyl group is 7-oxabicyclo[2.2.1]heptenyl. Preferred monocyclic thiaheterocyclenyl groups include dihydrothiophenyl and dihydrothiopyranyl; more preferred is dihydrothiophenyl. Preferred ring system substituents include amidino, halogen, hydroxy, alkoxycarbonylalkyl, carboxyalkyl and Y¹Y²N- as defined herein.

"Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system of about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms, in which one or more of the carbon atoms in the ring system is/are replaced by an atom of an element other than carbon (i.e., a "heteratom"), for example nitrogen, oxygen or sulfur. Preferred ring sizes of rings of the ring system include about 5 to 6 ring atoms. The designation of aza, oxa or thia as a prefix before the heterocyclyl means that at least a nitrogen, oxygen or sulfur atom is present,

respectively, as a ring atom. The heterocyclyl group may be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.

The nitrogen atom(s) of an heterocyclyl may be a basic nitrogen atom. The nitrogen or sulphur atom(s) of the heterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Representative monocyclic heterocyclyl groups include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, 2-thioxo-4-thiazolidinonyl, tetrahydrothiopyranyl, and the like. Preferred heterocyclyl groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, piperidyl. Preferred heterocyclyl group substituents include alkyl, aralkyl, amidino, halogen, hydroxy, aralkoxycarbonyl, alkoxycarbonylalkyl, carboxyalkyl and Y¹Y²N- as defined herein.

"Heterocyclylalkyl" means an heterocyclyl-alkyl- group wherein the heterocyclyl and alkyl portions are as herein described. Preferred heterocyclylalkyl groups contain a lower alkyl moiety. An exemplary heteroaralkyl group is tetrahydropyranylmethyl.

"Heterocyclylalkyloxyalkyl" means an heterocyclyl-alkyl-O-alkyl- group wherein the heterocyclyl and alkyls groups independently are as herein described. An exemplary heteroaralkyl group is tetrahydropyranylmethyloxymethyl.

"Heterocycliloxy" means a heterocyclyl-O- group in which the heterocyclyl group is as defined herein. Exemplary heterocycliloxy groups include quinuclidyloxy, pentamethylenesulfideoxy, tetrahydropyranyloxy, tetrahydrothiophenyloxy, pyrrolidinylloxy, tetrahydrofuranyloxy, 7-oxabicyclo[2.2.1]heptanyloxy, hydroxytetrahydropyranyloxy and hydroxy-7-oxabicyclo[2.2.1]heptanyloxy.

"Hydrate" means a solvate wherein the solvent molecules are H₂O.

"Hydroxyalkyl" means a HO-alkyl- group wherein alkyl is as herein defined. Preferred hydroxyalkyls contain lower alkyl. Exemplary preferred hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

"Hygroscopicity" means sorption, implying an acquired amount or state of water sufficient to affect the physical or chemical properties of the substance (Eds. J. Swarbrick and J. C. Boylan, Encyclopedia of Pharmaceutical Technology, Vol. 10, p. 33).

"Liquid dosage form" means that the dose of the active compound to be administered to the patient is in liquid form, for example, a pharmaceutically acceptable emulsion, solution, suspension, syrup and elixir. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances, and the like.

"Modulate" refers to the ability of a compound to either directly (by binding to the receptor as a ligand) or indirectly (as a precursor for a ligand or an inducer which promotes production of a ligand from a precursor) induce expression of a gene maintained under hormone control, or to repress expression of a gene maintained under such control.

"Patient" includes both human and other mammals.

"Pharmaceutical composition" refers to a composition comprising an active compound and at least one component selected from pharmaceutically acceptable carriers, diluents, adjuvants, excipients, vehicles, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms. Examples of suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures of these substances. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents that delay absorption, for example, aluminum monostearate and gelatin. Examples of suitable carriers, diluents, solvents or vehicles include water, ethanol, polyols, suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Examples of excipients include lactose, sodium citrate, calcium carbonate, and dicalcium phosphate. Examples of disintegrating agents include starch, alginic acids and certain complex silicates. Examples of lubricants include magnesium stearate, sodium lauryl sulphate, talc, and high molecular weight polyethylene glycols.

"Pharmaceutically acceptable" means that, within the scope of sound medical judgment, the item is suitable for use in contact with the cells of humans and lower animals without causing

undue toxicity, irritation, allergic response and the like, and is commensurate with a reasonable risk/benefit analysis.

5 "Pharmaceutically acceptable dosage forms" refers to dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, and solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.

10 "Pharmaceutically acceptable ester" refers to esters which hydrolyze *in vivo* and include those that break down readily in the patient's body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include formates, acetates, propionates, butyrates, acrylates and
15 ethylsuccinates.

"Pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without causing undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable risk/benefit
20 analysis, and are effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed *in vivo* to yield the parent compound, for example by hydrolysis in blood. Functional groups which may be rapidly transformed, by metabolic cleavage, *in vivo*, may be formed by reaction with the carboxyl group of the compounds of this invention. They include,
25 but are not limited to such groups as alkanoyl (such as acetyl, propionyl, butyryl, and the like), unsubstituted and substituted aroyl (such as benzoyl and substituted benzoyl), alkoxycarbonyl (such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethylsilyl), monoesters formed with dicarboxylic acids (such as succinyl), and the like. Because of the ease with which the metabolically cleavable groups of the compounds of this invention are cleaved *in vivo*,
30 compounds bearing such groups act as pro-drugs. The compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group. A thorough discussion of prodrugs is provided in Design of Prodrugs, H. Bundgaard, ed., Elsevier, 1985; Methods in Enzymology, . K. Widder et al, Ed., Academic Press, 42, p.309-396, 1985; A Textbook of Drug Design and
35 Developement, Krogsgaard-Larsen and H. Bundgaard, ed., Chapter 5; "Design and Applications of Prodrugs" p.113-191, 1991; Advanced Drug Delivery Reviews, H. Bundgard, 8, p.1-38, 1992; Journal of Pharmaceutical Sciences, 77, p. 285, 1988; Chem. Pharm. Bull., N. Nakeya et al, 32,


p. 692, 1984; Pro-drugs as Novel Delivery Systems, T. Higuchi and V. Stella, Vol. 14 of the A.C.S. Symposium Series, and Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, 1987, the contents of all of which are hereby incorporated herein by reference.

5 “Pharmaceutically acceptable salts” refers to the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.

10 Representative acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, sulphonates, malonates, salicylates, propionates, methylene-bis- β -hydroxynaphthoates, gentisates, isothionates, di-p-toluoyletartrates, 15 methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphonates, quinate, laurylsulphonate salts, and the like. (See, for example S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 66: p.1-19 (1977) the contents of which are hereby incorporated herein by reference.) Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and 20 isolating the salt thus formed. Base addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts. The sodium and potassium salts are preferred. Suitable inorganic base addition salts are prepared from metal bases, which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium 25 hydroxide, magnesium hydroxide, and zinc hydroxide. Suitable amine base addition salts are prepared from amines which have sufficient basicity to form a stable salt, and preferably include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use, such as ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, 30 procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephedrine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.g., lysine and arginine, and dicyclohexylamine, and the like.

35 “Solid dosage form” means that the dosage form of the compound of the invention is in solid form, for example, as capsules, tablets, pills, powders, dragees or granules. In such solid dosage forms, the compound of the invention is admixed with at least one inert customary excipient (or carrier), such as sodium citrate or dicalcium phosphate or one or more (a) fillers or

extenders, for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as, for example, glycerol, (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, for example, paraffin, (f) absorption accelerators, for example, quaternary ammonium compounds, (g) wetting agents, for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, for example, kaolin and bentonite, (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, and sodium lauryl sulfate, (j) opacifying agents, (k) buffering agents, and agents which release the compound(s) of the invention in a certain part of the intestinal tract in a delayed manner.

“Solid support” is represented as “” and means a substrate which is inert to the reagents and reaction conditions described herein, as well as being substantially insoluble in the media used. Representative solid supports include inorganic substrates such as kieselguhr, silica gel, and controlled pore glass; organic polymers including polystyrene, including 1-2% copolystyrene divinyl benzene (gel form) and 20-40% copolystyrene divinyl benzene (macro porous form), polypropylene, polyethylene glycol, polyacrylamide, cellulose, and the like; and composite inorganic/polymeric compositions such as polyacrylamide supported within a matrix of kieselguhr particles. See J.M. Stewart and J.D. Young, *Solid-phase Peptide Synthesis*, 2nd. Ed., Pierce Chemical Co. (Chicago, IL, 1984).

In addition, “solid support” includes a solid support as described above which is affixed to a second inert support such as the pins described in Technical Manual, Multipin™ SPOC, Chiron Technologies (1995) and references therein which comprise a detachable polyethylene- or polypropylene-based head grafted with an amino functionalized methacrylate copolymer and an inert stem.

In addition, “solid support” includes polymeric supports such as the polyethylene glycol supports described by Janda et al., *Proc. Natl. Acad. Sci. USA*, 92, 6419-6423 (1995) and S. Brenner, WO 95/16918, which are soluble in many solvents but can be precipitated by the addition of a precipitating solvent.

“Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice

of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Representative solvates include ethanolates, methanolates, and the like.

"Ring system substituents" mean substituents attached to aromatic or non-aromatic ring systems, and includes hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, cycloalkenyl, heterocyclenyl, heterocyclenyl, aryl diazo, heteroaryl diazo, amidino, Y^1Y^2N- , Y^1Y^2N -alkyl-, Y^1Y^2NCO- and $Y^1Y^2NSO_2-$, wherein Y^1 and Y^2 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl and optionally substituted heteroaralkyl, or, where the substituent is Y^1Y^2N- , then one of Y^1 and Y^2 may be acyl or aroyl as defined herein and the other of Y^1 and Y^2 is as defined previously, or where the substituent is Y^1Y^2NCO- or $Y^1Y^2NSO_2-$, Y^1 and Y^2 may also be taken together with the N atom through which Y^1 and Y^2 are linked to form a 4 to 7 membered heterocyclenyl or heterocyclenyl. Preferred ring system substituents are alkoxy carbonyl, alkoxy, halo, aryl, aralkoxy, alkyl, hydroxy, aryloxy, nitro, alkylsulfonyl, heteroaryl, Y^1Y^2N- . Most preferred ring system substituents are selected from alkoxy carbonyl, halo, aryl, aralkoxy, aralkyl, alkyl, hydroxy, aryloxy, Y^1Y^2N- , oxo, cyano, nitro, and arylsulfinyl. When a ring system is saturated or partially saturated, the "ring system substituents" further include, methylene ($H_2C=$), oxo ($O=$), thiooxo ($S=$).

" Y^1Y^2N- " means a substituted or unsubstituted amino group, wherein Y^1 and Y^2 are as herein described. Exemplary groups include amino (H_2N-), methylamino, dimethylamino, diethylamino, pyrrolidine, piperidine, benzylamino, or phenethylamino.

" Y^1Y^2NCO- " means a substituted or unsubstituted carbamoyl group, wherein Y^1 and Y^2 are as herein described. Exemplary groups are carbamoyl (H_2NCO-) and dimethylaminocarbamoyl (Me_2NCO-).

" $Y^1Y^2NSO_2-$ " means a substituted or unsubstituted sulfamoyl group, wherein Y^1 and Y^2 are as herein described. Exemplary groups are aminosulfamoyl (H_2NSO_2-) and dimethylaminosulfamoyl (Me_2NSO_2-).

"Primary or secondary protected amine" means a group of the following formula Y^aY^bN- wherein one of Y^a and Y^b is P^a , a nitrogen protecting group, and the other of Y^a and Y^b is hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclenyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclenyl, heterocyclenyl or heterocyclenyl.

"Activated carboxylic acid" means a group of the formula LO-CO- wherein L is an aliphatic, aromatic or a resin moiety.


In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.


5

Preferred Embodiments

One particular aspect of the present invention is directed to a method for preparing a cyclized compound selected from group of formulae consisting of 1,4-benzodiazepine-2,5-dione derivatives of general formulae (I), and (VII), diketopiperazine derivatives of general formula (II), ketopiperazine derivatives and dihydroquinoxalinone derivatives of general formula (III) and (VIII), dihydroimidazole derivatives of general formula (IV), lactam derivatives of general formula (V), 1,4-benzodiazepine-2,5-dione diketopiperazine derivatives of formula (VI), ketopiperazine derivatives of formula (XLII), cyclic urea derivatives of general formulae (L) and (LIII), and hydantoin derivatives of general formula (LV):-.

15





wherein:

- 5 $n = 1$ or 2 ;
 $m = 0$ or 1 ;
 $p = 2$;
 $q = 1$ or 2 ;

R¹ and R⁹ independently are selected from hydrogen, alkenyl, alkyl, aralkenyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl, and heterocyclyl;

R² is selected from hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl and heterocyclyl, or R¹ and R² taken together with the nitrogen atom and carbon atoms through which R¹ and R² are linked form a 6 membered heterocyclyl;

R^3 is selected from hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl and heterocyclyl.

R⁴ or R⁵ independently are selected from hydrogen, alkenyl, alkyl, aryl, alkynyl, aralkenyl, aralkynyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaralkenyl, heteroaralkynyl, fused heteroaryl cycloalkenyl, fused

heteroarylcycloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl and heterocyclenyl, or

R^4 and R^5 taken together with the carbon atom through which R^4 and R^5 are linked form a 3 to 7 membered cycloalkyl or cycloalkenyl;

5 R^6 , R^7 , R^8 and $R^{8'}$ independently are selected from hydrogen, alkenyl, alkenyloxy, alkoxy, alkyl, aryl, alkylsulfinylcarbamoyl, alkynyl, alkynyloxy, aralkenyl, aralkylsulfonyl, aralkynyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, aryloxy, carbonyl, cycloalkyloxy, heteroaralkenyl, heteroaralkyloxy, heteroaralkynyl, heteroaroyl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heteroarylsulphonylcarbamoyl, heterocycliloxy, heteroaryl, aralkyl, heteroaralkyl, hydroxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxy, carbonyl, aralkoxy, carbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, arylidazo, heteroarylidazo, amidino, Y^1Y^2N- , Y^1Y^2NCO- and $Y^1Y^2NSO_2-$, wherein Y^1 and Y^2 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or, where the substituent is Y^1Y^2N- , then one of Y^1 and Y^2 may be acyl or aroyl and the other of Y^1 and Y^2 is as defined previously, or, where the substituent is Y^1Y^2NCO- or $Y^1Y^2NSO_2-$, Y^1 and Y^2 may also be taken together with the N atom through which Y^1 and Y^2 are linked form a 4 to 7 membered heterocyclyl or heterocyclenyl, or

R^3 and $R^{8'}$ taken together with the nitrogen atom and carbon atoms through which R^3 and $R^{8'}$ are linked form a 5 to 7 membered heterocyclyl or heterocyclenyl, or two adjacent substituents selected from the substituents R^6 , R^7 , $R^{8'}$ and R^8 taken together with the aryl carbon atoms through which the two adjacent substituents are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl, or 6 membered aryl or 5 or 6 membered heteroaryl;

R^{14} , R^{15} , R^{10} and R^{11} independently are selected from hydrogen, alkenyl, alkyl, aryl, alkynyl, aralkenyl, aralkynyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaralkenyl, heteroaralkynyl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heteroarylsulphonylcarbamoyl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, or, when $n=1$, R^{11} and R^{14} are absent and R^{10} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 6 membered aryl or 5 or 6 membered heteroaryl;

or, when $n=1$, and R^{11} and R^{14} are present, R^{10} and R^{15} taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl;

or, when $n=2$, adjacent R^{11} and R^{14} are absent and R^{10} and adjacent R^{15} taken together with the adjacent carbon atoms through which they are linked form a 6 membered aryl or 5 to 6 membered heteroaryl;

or when $n=2$, and R^{11} and R^{14} are present, R^{10} and adjacent R^{15} taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl;

or when n or $p=2$, the adjacent R^{14} and R^{14} are absent and the adjacent R^{15} and R^{15} taken together with the adjacent carbon atoms through which they are linked, form a 6 membered aryl or 5 or 6 membered heteroaryl;

or when n or $p=2$, and the adjacent R^{14} and R^{14} are present, adjacent R^{15} and R^{15} taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl;

or when $m=1$, R^{11} and R^{14} are absent and R^{10} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 6 membered aryl or 5 or 6 membered heteroaryl;

or when $m=1$, and R^{11} and R^{14} are present, R^{10} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl;

R^{12} is selected from alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl and heterocyclyl; and

R^{16} is selected from hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, heteroaralkenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl and heterocyclyl, or R^9 and R^{16} together with the carbon atoms and nitrogen atom through which they are attached form a 5-8 membered heterocyclyl group.

In one aspect, this invention is directed to a solution phase synthesis of a compound of formula (I) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., *Angew. Chem. Int. Ed. Engl.*, 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XIV) with an aldehyde or ketone of formula (XV), an amine of formula (XVI), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XVII), and nitrogen-deprotection of the intermediate compound, and cyclization to form the compound of formula (I). Hulme, C.; Tang, S-Y.; Burns, C. J.; Morize, I.; Labaudiniere, R. *J. Org. Chem.* 1998, 63, 8021.

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (I) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction

(MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XIV) with an aldehyde or ketone of formula (XV), an amine of formula (XVI), and a resin bound isonitrile selected from (IXa) and (XVIII) to form the respective intermediate resin bound compound, nitrogen-deprotection of the intermediate
5 compound, and cyclization and decoupling of the resin to form the compound of formula (I).

In one aspect, this invention is directed to a solution phase synthesis of a compound of formula (Ia) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XIV) with an aldehyde or ketone of formula (XVa), an amine
10 of formula (XVIa), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XVIIa), and nitrogen-deprotection of the intermediate compound, and cyclization to form the compound of formula (Ia).

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (Ia) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XIV) with an aldehyde or ketone of formula (XVa), an amine
15 of formula (XVIa), and a resin bound isonitrile selected from (IXa) and (XVIII) to form the respective intermediate resin bound compound, nitrogen-deprotection of the intermediate compound, and cyclization and decoupling of the resin to form the compound of formula (Ia).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (II) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising a nitrogen-protected amino acid of formula (XXII) with an aldehyde or ketone of formula (XV), an amine of formula (XVI),
20 and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XXIII), and nitrogen-deprotection of the intermediate compound and cyclization to form the compound of formula (II). Hulme, C.; Morrisette, M. M.; Volz, F. A.; Burns, C. J. *Tetrahedron Lett.* 1998, 39, 113.

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (II) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XXII) with an aldehyde or ketone of formula (XV), an amine of
30 formula (XVI), and a resin bound isonitrile selected from (IXa) and (XVIII) to form the respective intermediate resin bound compound, nitrogen-deprotection of the intermediate compound, and cyclization and decoupling of the resin to form the compound of formula (II).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (IIa) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising a nitrogen-protected amino acid of formula (XXII) with an aldehyde or ketone of formula (XVa), an amine of formula
35

(XVIa), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XXIIIa), and nitrogen-deprotection of the intermediate compound and cyclization to form the compound of formula (IIa).

5 In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (IIa) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XXII) with an aldehyde or ketone of formula (XVa), an amine of formula (XVIa), and a resin bound isonitrile selected from (IXa) and (XVIII) to form the
10 respective intermediate resin bound compound (XXIIIa), nitrogen-deprotection of the intermediate compound, and cyclization and decoupling of the resin to form the compound of formula (IIa).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (III) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting an acid of formula
15 (XXVI) with an aldehyde or ketone of formula (XV), a diamine of formula (XXVII), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XXVIII) and nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (III). Hulme, C.; Peng, J.; Louridas, B.; Menard, P.; Krolikowski, P.; Kumar, N. V. *Tetrahedron Lett.* 39, 7227.

20 In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (III) via a '3-step, one pot' procedure, employing the Ugi multi-comprising reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) combining reacting an acid of formula (XXVI) with an aldehyde or ketone of formula (XV), a diamine of formula (XXVII), and a resin bound isonitrile selected from (IXa) and (XVIII) to form the respective intermediate resin bound
25 compound, nitrogen-deprotection of the intermediate compound and cyclization and decoupling of the resin to form the compound of formula (III).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (IIIa) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting an acid of formula
30 (XXVIa) with a diamine of formula (XXVII), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XXVIIIa) and nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (IIIa).

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (IIIa) via a '3-step, one pot' procedure, employing the Ugi multi-comprising reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) combining reacting an acid of formula
35 (XXVIa) with a diamine of formula (XXVII), and a resin bound isonitrile selected from (IXa) and (XVIII) to form the respective intermediate resin bound compound (XXVIII), nitrogen-

deprotection of the intermediate compound and cyclization and decoupling of the resin to form the compound of formula (IIIa).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (IV) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., *Angew. Chem. Int. Ed. Engl.*, 1962, 1, 8) comprising reacting a nitrogen-protected amino aldehyde of formula (XXXIII) with acid of formula (XXVI), an amine of formula (XVI), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XXXIV), and nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (IV). The non-cyclized amines are removed via a solution phase scavenging step with the simultaneous addition of PS-DIEA or PS-tris(2-aminoethyl)amine (6 equiv.) and PS-NCO (3 equiv.) in dichloroethane. (Booth, R.J.; Hodges, J.C. *J. Am. Chem. Soc.* 1997, 119, 4882. Flynn, D.L.; Crich, J. Z.; Devraj, R. V.; Hockerman, S.L.; Parlow, J.J.; South, M.S.; Woodward, S. *J. Am. Chem. Soc.* 1997, 119, 4874. Purchased from Argonaut[®] technologies (PS-DIEA = polystyrene bound diisopropylethylamine)).

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (V) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., *Angew. Chem. Int. Ed. Engl.*, 1962, 1, 8) comprising reacting a nitrogen-protected amino aldehyde or ketone of formula (XXXV), an amine of formula (XVI), an acid of formula (XXVI) and a resin bound isonitrile selected from (IXa) or (XVIII) to form the respective intermediate resin bound compound, nitrogen-deprotection of the intermediate compound, and cyclization and decoupling of the resin to form the compound of formula (V).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (VI) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., *Angew. Chem. Int. Ed. Engl.*, 1962, 1, 8) comprising a nitrogen-protected amino acid of formula (XIV) with an aldehyde or ketone of formula (XXXVII), an amine of formula (XVI), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XXXVIII) and nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (VI).

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (VI) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., *Angew. Chem. Int. Ed. Engl.*, 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XIV) with an aldehyde or ketone of formula (XXXVII), an amine of formula (XVI), and a resin bound isonitrile of formula (XVIII) to form an intermediate compound and nitrogen-deprotection of the intermediate compound, and cyclization and decoupling of the resin to form a compound of formula (VI).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (VII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction

(MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XIV), a suitable non-resin bound α -amino ester, a non-resin bound isonitrile (IX), and an aldehyde or ketone of formula (XV), to form an intermediate compound and nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (VII).

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (VII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XIV), a resin bound α -amino ester of formula (XXXIX), and a non-resin bound isonitrile (IX) and an aldehyde or ketone of formula (XV), to form the intermediate resin bound compound (XL) and nitrogen-deprotection of the intermediate compound, and cyclization and decoupling of the resin to form the compound of formula (VII).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (VIII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting an acid of formula (XXVI) with a compound of formula (XXXVII), a diamine of formula (XXVII), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XLI), nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (VIII).

In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (VIII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising an acid of formula (XXVI) with a compound of formula (XXXVII), a diamine of formula (XXVIIa), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (XLI), nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (VIII).

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (VIII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting an acid of formula (XXVI) with (XXXVII), a diamine of formula (XXVII), and a resin bound isonitrile of formula (IXa) or (XVIII) to form an intermediate, nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (VIII), wherein R^{12} represents the resin portion of the resin bound isonitrile derivative.

In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (XLII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting a nitrogen-protected amino acid of formula (XLIII), a resin bound α -amino ester of formula (XXXIX), a non-resin bound isonitrile (IX) and an acid of formula (XXVI), to form the intermediate resin

bound compound (XLIX), nitrogen-deprotection of the intermediate compound and cyclization and decoupling of the resin to form the compound of formula (XLII).

5 In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (L) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising an acid of formula (LI) with an aldehyde or ketone of formula (XV), a diamine of formula (XXVII), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (LII), nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (L).

10 In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (L) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting an acid of formula (LI) with an aldehyde or ketone of formula (XV), a diamine of formula (XXVII), and a resin bound isonitrile of formula (IXa) or (XVIII) to form an intermediate, nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (L).

15 In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (LIII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising an acid of formula (LI) with an aldehyde or ketone of formula (XXXIII), an amine of formula (VI), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (LIV), nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (LIII).

20 In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (LIII) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting an acid of formula (LI) with an aldehyde or ketone of formula (XXXIII), an amine of formula (XVI), and a resin bound isonitrile of formula (IXa) or (XVIII) to form an intermediate of formula (LIV), nitrogen-deprotection of the intermediate compound (LIV) and cyclization to form a compound of formula (LIII).

25 In another aspect, this invention is directed to a solid phase synthesis of a compound of formula (LV) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising reacting an acid of formula (LI) with an aldehyde or ketone of formula (XV), an amine of formula (XVI), and a resin bound isonitrile of formula (IXa) or (XVIII) to form an intermediate of formula (LVI), nitrogen-deprotection of the intermediate compound (LVI) and cyclization to form a compound of formula (LV).


30 In another aspect, this invention is directed to a solution phase synthesis of a compound of formula (LV) via a '3-step, one pot' procedure, employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) comprising an acid of formula (LI)

with an aldehyde or ketone of formula (XV), an amine of formula (XVI), and a non resin bound isonitrile of formula (IX) to form an intermediate compound of formula (LVI), nitrogen-deprotection of the intermediate compound and cyclization to form a compound of formula (LV).

In another aspect, this invention is directed to the preparation of
5 1,4-benzodiazepine-2,5-dione derivatives of general formulae (I) and (VI), diketopiperazine derivatives of general formula (II), ketopiperazine derivatives and dihydroquinoxalinone derivatives of general formula (III) and (VIII), dihydroimidazole derivatives of general formula (IV), lactam derivatives of general formula (V), cyclic urea derivatives of general formulae (L) and (LIII), and hydantoin derivatives of general formula (LV), by solid phase synthesis
10 employing the Ugi multi-component reaction (MCR) (Ugi, I., *Angew. Chem. Int. Ed. Engl.*, 1962, 1, 8) using an isonitrile functionalized polymer resin linker (IXa) as described herein, followed by amine deprotection, cleavage from the resin and cyclization. The alkoxide and hydroxide safety-catch clipping strategy and subsequent solution phase cyclization offers similar advantages to a traceless linker (Plunkett, M.J.; Ellman, J.A. *J. Org. Chem.* 1995, 60, 6006;
15 Hulme, C.; Peng, J.; Morton, G.; Salvino, J.M.; Herpin, T.; Labaudiniere, R. *Tetrahedron Lett.* 1998, 39,) in that no constant functionality derived from clipping remains at the end of the synthetic protocol.

In another aspect, this invention is directed to the preparation of
ketopiperazine derivatives of general formula (XLII) and 1,4-benzodiazepine-2,5-dione
20 derivatives of general formula (VII), by solid phase synthesis employing the Ugi multi-component reaction (MCR) (Ugi, I., *Angew. Chem. Int. Ed. Engl.*, 1962, 1, 8) using an amino ester bound polymer resin linker (XXXIX) as described herein, followed by amine deprotection, cleavage from the resin and cyclization.

In another aspect, this invention is directed to the preparation and use of a novel resin
25 bound isonitrile (IXa), deployed as a novel safety catch linker (Backes, B. J., Virgilio, A. A., Ellman, J. A. *J. Am. Chem. Soc.* 1996, 118, 3055; Kenner, G. W., McDermott, J. R., Sheppard, R. C. *J. Chem. Soc., Chem. Commun.* 1971, 636.) in the preparation of 1,4-benzodiazepine-2,5-dione derivatives of general formulae (I), (VI) and (VII), diketopiperazine derivatives of general formula (II), ketopiperazine derivatives and dihydroquinoxalinone derivatives of general formula (III) and (VIII), dihydroimidazole or imidazoline derivatives of general formula (IV), and lactam
30 derivatives of general formula (V).



A preferred aspect of the compounds produced by the methods of the invention are those wherein:

$n = 1$ or 2 .

5 A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

$m = 0$ or 1 .

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R^1 is aralkyl, alkyl, aryl, heteroaryl, cycloalkyl, aralkenyl, heterocyclenyl or heterocyclyl.

10 A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R^1 is hydrogen or alkyl.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

15 R^2 is selected from heteroaralkyl, aralkyl, alkyl, fused arylcycloalkyl, cycloalkyl, heterocyclyl, aryl, fused arylheterocyclenyl, and fused arylheterocyclyl.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

20 R^3 is selected from hydrogen, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heterocyclenyl, and heterocyclyl.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

25 R^4 and R^5 independently are selected from hydrogen, alkyl, aralkyl, aryl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, heterocyclenyl or heterocyclyl.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

30 R^6 , R^7 , R^8 and $R^{8'}$ independently selected from hydrogen, alkenyl, alkyl, aryl, aralkyl, heteroaralkyl, hydroxy, aryloxy, alkoxy, aralkoxy, halo, nitro, cyano, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heteroarylsulphonylcarbamoyl, heteroaryl, Y^1Y^2N- , or $Y^1Y^2NSO_2-$.

35 A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R^{15} is absent and R^3 and R^{14} taken together with the nitrogen atom and carbon atom through which R^3 and R^{14} are linked form a 6 membered aryl or 5 to 6 membered heteroaryl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R^4 and R^5 taken together with the carbon atom through which R^4 and R^5 are linked form a 3 to 7 membered cycloalkyl or cycloalkenyl ring.

5 A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

two adjacent substituents selected from the substituents R^6 , R^7 , $R^{8'}$ and R^8 taken together with the aryl carbon atoms through which the two adjacent substituents are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl, or 6 membered aryl or 5 to 6 membered heteroaryl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R^{10} , R^{11} , R^{14} and R^{15} independently are selected from hydrogen, alkyl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, and aralkyl.

15 A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

$n=1$, R^{11} and R^{14} are absent and R^{10} and R^{15} taken together with the adjacent carbon atoms through which they are linked form a 6 membered aryl or 5 to 6 membered heteroaryl ring.

20 A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

$n=1$, R^{10} and R^{15} taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

25 $n=2$, adjacent R^{11} and R^{14} are absent, and R^{10} and adjacent R^{15} taken together with the adjacent carbon atoms through which they are linked form a 6 membered aryl or 5 to 6 membered heteroaryl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

30 $n=2$, R^{11} and R^{14} are present, and R^{10} and adjacent R^{15} taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

35 n or $p=2$, adjacent R^{14} and R^{14} are absent, and adjacent R^{15} and R^{15} taken together with the adjacent carbon atoms through which they are linked form a 6 membered aryl or 5 to 6 membered heteroaryl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

n or p =2, and adjacent R¹⁴ and R¹⁴ are present, and adjacent R¹⁵ and R¹⁵ taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

m=1, R¹¹ and R¹⁴ are absent and R¹⁰ and R¹⁵ taken together with the adjacent carbon atoms through which they are linked form a 6 membered aryl or 5 to 6 membered heteroaryl ring.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

m=1, R¹¹ and R¹⁴ are present, and R¹⁰ and R¹⁵ taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R¹⁶ is selected from hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, heteroaralkenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused arylcycloalkyl, fused heteroaryl heterocyclyl, heterocyclenyl and heterocyclyl.

A preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R¹⁶ is selected from alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, heteroaralkenyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl or heterocyclyl.

A more preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R⁶, R⁷, R⁸ and R^{8'}, independently are selected from hydrogen, halo, alkoxy, alkyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, or heteroaryl.

A more preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R¹⁰, R¹¹, R¹⁴ and R¹⁵ independently are selected from hydrogen, alkyl, and aralkyl.



A more preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:

R^{12} is selected from alkyl, aralkyl, aryl, cycloalkyl, and heterocyclyl.



A more preferred aspect of the compounds prepared by the methods of the invention is those compounds wherein:













R^{16} is selected from alkyl, fused arylheterocyclyl, aralkyl, cycloalkyl, heteroaryl, aryl,
 5 heteroaralkyl, alkenyl, heteroaralkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused
 heteroarylcyloalkenyl, fused heteroarylheterocyclyl, heterocyclenyl and heterocyclyl.
















A preferred compound prepared according to the invention is selected from the group of compounds having the following formulae:



















10






































5









and

It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

The compounds prepared by the methods of the invention optionally are supplied as salts.

- 5 Those salts which are pharmaceutically acceptable are of particular interest since they are useful in administering the foregoing compounds for medical purposes. Salts which are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some instances, for use in separating stereoisomeric forms of the compounds of this invention. The latter is particularly true of amine salts prepared from optically active
- 10 amines.

Where the compound of the invention contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free acid form.

- Also, where the compound of the invention contains a basic group, or a sufficiently basic
- 15 bioisostere, acid addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form.

- While it is possible for the compounds of the invention to be administered alone, it is preferably to present them as pharmaceutical compositions. The pharmaceutical compositions, both for veterinary and for human use, of the present invention comprise at least one compound
- 20 of the invention, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients.

- The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice.
- 25 For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used, they can contain emulsifying

agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the emulsifying wax, and the wax together with the oil and fat make up the emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

If desired, the aqueous phase of the cream base may include, for example, a least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups, such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters, such as di-isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP, may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Solid compositions may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.

The pharmaceutical compositions can be administered in a suitable formulation to humans and animals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the preferred route may vary with, for example, the condition of the recipient.

The formulations can be prepared in unit dosage form by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier, which may constitute one or more accessory ingredients. In general,

the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

5 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form, such as a powder or granules, optionally mixed with one or more of a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Moulded tablets may be made by moulding, in a suitable machine, a mixture of the powdered compounds moistened with an inert liquid diluent. The tablets may optionally be
10 coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

If desired, and for more effective distribution, the compounds can be microencapsulated
15 in, or attached to, a slow release or targeted delivery system, such as a biocompatible, biodegradable polymer matrix (e.g. poly(d,l-lactide co-glycolide)), liposomes, and microspheres, and subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot, to provide continuous slow release of the compound(s) for a period of 2 weeks or longer. The compounds may be sterilized, for example, by filtration through a bacteria
20 retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.

Actual dosage levels of active ingredient in the compositions of the invention may be varied so as to obtain an amount of active ingredient that is effective to obtain a desired
25 therapeutic response for a particular composition and method of administration. The selected dosage level, therefore, depends upon the desired therapeutic effect, on the route of administration, on the desired duration of treatment and other factors.

Total daily dose of the compounds of this invention administered to a host in single or divided doses may be in amounts, for example, of from about 0.001 to about 100 mg/kg body
30 weight daily, and preferably 0.01 to 10 mg/kg/day. Dosage unit compositions may contain such amounts or such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors, including the body weight, general health, sex, diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity
35 of the particular disease being treated.

The amount of each component administered is determined by the attending clinicians taking into consideration the etiology and severity of the disease, the patient's condition and age, the potency of each component and other factors.


The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition, requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Preparation of Compounds of the Invention

The starting materials and intermediates used in the preparation of compounds according to the invention may be prepared by the application or adaptation of known methods, for example, methods described in the Reference Examples or their obvious chemical equivalents.

In the reactions described hereinafter, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, particularly where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice. For examples, see T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991; J. F. W. McOmie in "Protective Groups in Organic Chemistry" Plenum Press, 1973.

General methodology for the preparation the isonitrile resin linker of formula (IXa)



Reagents and Conditions:- (i) Wang resin, 4-nitrophenylchloroformate (5 equiv.), *n*-methyl morpholine (10 equiv.), THF. (ii) 2-(4 amino phenyl)ethylamine (5 equiv.), DMF. (iii) Formic acid (excess), acetic anhydride (excess), CH₂Cl₂ (iv) Ph₃P (5 equiv.), CCl₄ (5 equiv.), Et₃N (5 equiv.), CH₂Cl₂.

Experimental Procedures

Nitrocarbonate Resin of formula (XI) :

Wang resin (X) (100.0 g, 109.0 mmol) is swelled in anhydrous THF (1500 ml). *N*-methyl morpholine (119.8 ml, 1090.0 mmol) and 4-nitrophenyl chloroformate (109.86 g, 545 mmol) are added sequentially. The reaction is cooled in an ice bath for several minutes to quench the slightly exothermic reaction. The ice bath is then removed and the reaction is allowed to

warm to room temperature. It is mixed on an orbital shaker at RT overnight. The reaction solution is drained off and the resin is washed with THF (5X), 20% H₂O in DMF (5X), DMF (5X), THF (5X), and Et₂O (5X). The resin product (XI) is then placed in a vacuum oven at RT overnight to dry. IR analysis showed two sharp peaks at 1520 cm⁻¹ and 1350 cm⁻¹ for the NO₂ group.

Aniline Resin of formula (XII)

The nitrocarbonate resin (XI) (115.0 g, 125.35 mmol) is swelled in anhydrous DMF (1250 ml). 2-(4-Aminophenyl)ethylamine (82.6 ml, 626.75 mmol) is added to the resin slurry. The reaction mixture is mixed on an orbital shaker at RT overnight. The reaction solution is drained off and the resin is washed with DMF (8X). The still swollen resin is suspended in anhydrous DMF (1000 ml) and a second coupling of the amine (82.6 ml) is run overnight. After draining and washing with DMF (8X) a third coupling is run overnight. The final reaction solution is drained off and the resin product (XII) is washed with DMF (10X), THF (10X), and Et₂O (10X). The resin is then dried in a vacuum oven at RT overnight. IR analysis showed loss of the NO₂ peaks.


Formamide Resin (XIII):

The aniline resin (XII) (109.0 g, 86.1 mmol) is swelled in anhydrous CH₂Cl₂ (1000 ml). Formic acid (500 ml) and acetic anhydride (500 ml) are combined, and the resulting exothermic reaction is cooled in an ice bath. Once at RT, the resulting solution is allowed to sit at RT for 40 minutes. This mixed anhydride solution is then added to the resin slurry. The reaction mixture is mixed on an orbital shaker at RT overnight. The reaction solution is drained off, and the resin is washed with CH₂Cl₂ (10X). To remove any remaining acetic acid, the resin is washed with 20% H₂O in THF (6X) until the washings are neutral to litmus paper. The resin product (XIII) is finally washed with THF (10X) and Et₂O (8X) and then dried in a vacuum oven at RT overnight. IR analysis shows a strong carbonyl stretch for the formamide at 1698 cm⁻¹.

Isonitrile Resin of formula (IXa):


The formamide resin (XIII) (50.0 g, 44.5 mmol) is swelled in anhydrous CH₂Cl₂ (500 ml). Triphenylphosphine (58.4 g, 222.5 mmol), carbon tetrachloride (21.5 ml, 222.5 mmol), and triethylamine (31.0 ml, 222.5 mmol) are added sequentially at RT. The reaction mixture is mixed on an orbital shaker for 4.5 hours at RT. The reaction solution is drained off and the resin product (IXa) is washed with CH₂Cl₂ (20X), THF (10X), and Et₂O (10X). The resin is then placed in a vacuum oven at RT overnight to dry. IR analysis shows a sharp peak for the isonitrile at 2121 cm⁻¹.

General methodology for the preparation of 1,4-Benzodiazepine-2,5-diones (I)



(I)


In general terms, compounds of formula (I) wherein R¹, R², R³, R⁸, R⁶, R⁷, R⁸ and R⁹ are as hereinbefore defined, may be synthesized by reacting a compound of formula (XIV) wherein R³, R⁸, R⁶, R⁷ and R⁸ are as hereinbefore defined and Z¹ is a suitable amine protecting group, with a compound of formula (XV) wherein R¹ and R⁹ are as hereinbefore defined, a compound of formula (XVI) wherein R² is as hereinbefore defined, and a compound of formula (IX) wherein R¹² represents alkyl, aralkyl, aryl, fused arylcycloalkyl, fused arylheterocyclyl, cycloalkyl, heteroaralkyl, heteroaryl, fused heteroarylcycloalkyl, fused heteroarylheterocyclyl, or heterocyclyl; in a suitable solvent at about room temperature, to afford the intermediate compound (XVII), wherein R¹, R², R³, R⁸, R⁶, R⁷, R⁸, R⁹, R¹² and Z¹ are as hereinbefore defined. The general reaction is illustrated in scheme 1 below:




Scheme 1

The conversion of the compound (XVII) to the compound of formula I is described hereinafter with reference to Scheme 2. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved (See Waki et al. J. Am. Chem. Soc., 1977, 6075-6077, the contents of which are hereby incorporated herein by reference). Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, and hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, and dimethylformamide; halides, such as dichloromethane, and dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulfoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.


There is no restriction on the isonitrile of formula (IX) used in the reaction scheme 1 above, provided that it has no adverse effect on the reaction involved. Examples of suitable isonitriles include, 1-isocyanocyclohexene, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide also the isonitrile described in Ugi et al., Tetrahedron, 1999, 55, 7411-7420, the contents of which are hereby incorporated herein by reference. Preferable isonitriles include the isonitrile functionalized polymer resin of formula (IXa) or of formula (XVIII), 1-isocyanocyclohexene of formula (IXb), benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate. More preferably, isonitriles used in the reaction are isonitrile functionalized polymer resin of formula (IXa)



or the isonitrile functionalized polymer resin of formula (XVIII) (A. Piscopio, ORG Poster 232, American Chemical Society Meeting, Las Vegas, NV, 7-10 Sept., 1997):



or 1-isocyanocyclohexene of formula (IXb):




The use of resin bound isonitriles of formula (IXa) or of formula (XVIII) in the synthesis of compounds of the formula (I), (II), (III) (IV), (V), (VI), (VII), (VIII), (XLII), (L), (LIII), and (LV) is advantageous over the use of other non-resin bound isonitriles. The use of the resin bound isonitriles allow excess amount of reagents to be used in the reaction to drive the Ugi reaction forward. Also, unlike solution phase procedures, these reagents can be easily removed by subsequent washing of the resin, leaving the Ugi product clean and resin bound.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction

may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of the formula (XVII) thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling off the solvent in vacuo from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography. The intermediate compound is preferably recovered from the reaction mixture by distilling off the solvent in vacuo.

The intermediate compound (XVII) may be converted to a compound of formula (I) by reacting with acid and optionally base, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group (Z^1), followed by cyclization. This reaction is illustrated in Scheme 2.



Scheme 2

20

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 2 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of a base labile amine protecting group Z^1 , may equally

30


be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

5 In situations where acidic conditions are used to remove the amine protecting group in intermediate compound of formula (XVII) it may also be necessary to treat the deprotected intermediate, which is present as an acid salt, with base so as to convert the acid addition salt to its corresponding free base. There is no particular restriction on the nature of the base to be used. A base conventionally used to convert an acid addition salt to its corresponding free base form
10 of suitable bases include ammonia, piperidine, morpholine, ethanolamine, diethylamine, polystyrene bound di-isopropylethylamine or basic DOWEX. Preferably diethylamine, basic DOWEX or polystyrene bound di-isopropylethylamine.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the
15 reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.


20 There is no particular restriction on the amine protecting group (Z^1) employed. However, amino acid protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl
25 (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

Furthermore, a piperazinyl intermediate of formula (XVIIa); i.e. an intermediate of formula (XVII) wherein R^1 and R^2 together with the nitrogen and carbon atoms through which R^1 and R^2 are attached form a piperazinyl group; is formed by reacting an amine of formula (XVIa);
30 i.e. an amine of formula (XVI) wherein R^2 is $C(R^{19}R^{19'})C(R^{20}R^{20'})NY^1Y^2$, and Y^1 is hydrogen, Y^2 is independently, hydrogen, alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and R^{19} , $R^{19'}$, R^{20} , and $R^{20'}$ are independently optionally substituted alkyl; with an aldehyde or ketone of formula (XVa); i.e. an amine of formula (XV) wherein R_1 is a $CR^{21}R^{21'}X'$ and R^{21} and $R^{21'}$ are independently optionally substituted alkyl and X' is an appropriate leaving, for example a
35 halogen atom; an N-protected amino acid of formula (XIV) and an isonitrile of formula (IX), under conditions analogous to those described for synthesizing intermediate of formula (XVII) in scheme 1 and as described in Rossen et al., Tetrahedron et Lett. 1997, 38, 3183, the contents of which are hereby incorporated by reference.




Scheme 2a

The piperazinyl intermediate of formula (XVIIa) can then undergo further cyclisation to afford compounds of formula (Ia) i.e. compounds of formula I, wherein R¹ and R² together with the nitrogen and carbon atoms through which R¹ and R² are attached form a piperazinyl group. The cyclisation of piperazinyl intermediate of formula (XVIIa) to afford the compound of formula (Ia) is carried out under conditions analogous to those described for synthesizing compound of formula (I) in scheme 2 above.




Scheme 2b

The use of the novel resin bound isonitrile of formula (IXa) in the synthesis of compounds of the formula (I), wherein R¹² is the novel resin bound isonitrile derivative of formula (IXa), is advantageous over other non-resin bound isonitriles. However, use of a compound of formula (IXa) in the synthesis of a compound of formula (I) involves activation of the resin linker to facilitate cleavage of the resin linkage and cyclization to afford a compound of formula (I). An illustration of the use of the novel resin bound isonitrile of formula (IXa) in the synthesis of the intermediate formula (XIX) is illustrated in Scheme 3.



Scheme 3

Activation of the benzamide carbonyl of (XIX) to give the intermediate of formula (XX), wherein Z² is a carbamate protective group promotes facile cleavage from the resin. Examples of carbamate protective groups which may activate cleavage of the benzamide group, provided that they have no adverse effect on the reaction involved are, for example, t-butyl-O-CO- (BOC), benzyl-O-CO- (CBZ), Cl₃CCH₂-O-CO- (Troc), (CH₃)₃SiCH₂CH₂-O-CO- (TEOC), 1-methyl-1-(4-biphenyl)ethyl-O-CO- (BPOC) and cycloalkyl-O-CO-. Other carbamate protective groups include those described in 'Protecting groups in Organic Synthesis' Greene, 1981, p. 223-49. An example of the activation of the benzamide group is illustrated in Scheme 4, wherein Z²X a suitable carbamate protective group reagent, for example (BOC)₂O.




Scheme 4

The reaction conditions and reagents used in the activation of the benzamide, are ones that are known in the art of for the conversion of an amine to a carbamate group. This sort of reaction is usually carried out in dichloromethane, in the presence of a base, for example Et₃N, and a catalytic amount of DMAP. (For other suitable reaction conditions, see 'Protecting groups in Organic Synthesis' Greene, 1981, p. 223-49).


The resin "safety catch" linker is then cleaved, to facilitate the removal of the resin, by reacting the activated benzamide compound of formula (XX) with an appropriate alkoxide, or hydroxide, to afford the corresponding alkyl ester or carboxylic acid derivative of formula (XXI) respectively, wherein R¹³ is, for example, H, alkyl, phenyl or cycloalkyl (Mjalli, A.M.M., Sarshar, S., Baiga, T.J. *Tetrahedron Lett.* 1996, 37, 2943; Flynn, D. L., Zelle, R. E., Grieco, P. A.

J. Org. Chem. 1983, 48, 2424.) An example of the cleavage from the resin is illustrated in reaction Scheme 5:



Scheme 5

The intermediate compound of formula (XXI) may be converted to a compound of formula (I) by reacting with acid, in a suitable solvent and at an appropriate temperature, to effect removal of the amine protecting group (Z^1), followed by cyclization. This reaction is illustrated in Scheme 6.



Scheme 6

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 6 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.


This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

There is no particular restriction on the amine protecting group (Z^1) employed. However, amino acid protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

In situations where acidic conditions are used to remove the amine protecting group in intermediate compound of formula (XXI) it may also be necessary to treat the deprotected intermediate, which is present as an acid salt, with base so as to convert the acid addition salt to its corresponding free base. There is no particular restriction on the nature of the base to be used. A base conventionally used to convert an acid addition salt to its corresponding free base form may be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include ammonia, piperidine, morpholine, ethanolamine, diethylamine, polystyrene bound di-isopropylethylamine or basic DOWEX. Preferably diethylamine, basic DOWEX or polystyrene bound di-isopropylethylamine.

Similarly, solid phase synthesis of a compound of formula (I) can be carried out using the resin bound isonitrile of formula (XVIII) using reaction conditions similar to those described for scheme 1 and scheme 2.


General methodology for the preparation of diketopiperazines (II)



(II)

Compounds of formula II may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, or by methods according to this invention described and claimed herein.


In general terms, compounds of formula (II) wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^9 are as hereinbefore defined and Z^1 is a suitable amine protecting group, may be synthesized by reacting an amino acid of formula (XXII), wherein R^3 , R^4 , R^5 and Z^1 are as hereinbefore defined, with compounds of formula (XV) wherein R^1 and R^9 are as hereinbefore defined, a compound of formula (XVI) wherein R^2 is as hereinbefore defined, and a compound of formula (IX) wherein R^{12} is as hereinbefore defined, in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XXIII). This reaction is illustrated in Scheme 7 below:



Scheme 7

The reaction conditions used for the synthesis of intermediate of formula (XXIII), illustrated in Scheme 7, are similar to those described for the synthesis of intermediate of formula (XVII) illustrated in Scheme 1.

The intermediate compound of formula (XXIII) may be converted to a compound of formula (II) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group (Z^1), followed by cyclization. This reaction is illustrated in Scheme 8 below.



Scheme 8

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 8 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the

amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule.

- 5 Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.


This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

- There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

- In situations where acidic conditions are used to remove the amine protecting group in intermediate compound of formula (XXIII) it may also be necessary to treat the deprotected intermediate, which is present as an acid salt, with base so as to convert the acid addition salt to its corresponding free base. There is no particular restriction on the nature of the base to be used. A base conventionally used to convert an acid addition salt to its corresponding free base form may be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include ammonia, piperidine, morpholine, ethanolamine, diethylamine, polystyrene bound di-isopropylethylamine or basic DOWEX. Preferably diethylamine, basic DOWEX or polystyrene bound di-isopropylethylamine.

- Furthermore, a piperazinyl intermediate of formula (XXIIIa); i.e. an intermediate of formula (XXIII) wherein R^1 and R^2 together with the nitrogen and carbon atoms through which R^1 and R^2 are attached form a piperazinyl group; is formed by reacting an amine of formula (XVIa); i.e. an amine of formula (XVI) wherein R^2 is $C(R^{19}R^{19'})C(R^{20}R^{20'})NY^1Y^2$, and Y^1 is hydrogen, Y^2 is independently, hydrogen, alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and R^{19} , $R^{19'}$, R^{20} , and $R^{20'}$ are independently optionally substituted alkyl; with an aldehyde or ketone of formula (XVa); i.e. an aldehyde or ketone of formula (XV) wherein R_1 is a $CR^{21}R^{21'}X'$ and R^{21} and $R^{21'}$ are independently optionally substituted alkyl and X' is an appropriate leaving, for example a halogen atom; an N-protected amino acid of formula (XXII) and an isonitrile of


formula (IX), under conditions analogous to those described for synthesizing intermediate of formula (XXIII) in scheme 7 and as described in Rossen et al., Tetrahedron et Lett. 1997, 38, 3183, the contents of which are hereby incorporated by reference. This reaction is illustrated in Scheme 8a.



Scheme 8a


The piperazinyl intermediate of formula (XXIIIa) can then undergo further cyclisation to afford compounds of formula (IIa) i.e. compounds of formula II, wherein R¹ and R² together with the nitrogen and carbon atoms through which R¹ and R² are attached form a piperazinyl group.

This reaction is illustrated in Scheme 8b. The cyclisation of piperazinyl intermediate of formula (XXIIIa) to afford the compound of formula (IIa) is carried out under conditions analogous to those described for synthesizing compound of formula (II) in scheme 8 above.



Scheme 8b


The use of the novel resin bound isonitrile of formula (IXa) in the synthesis of compounds of the formula (XXIII), wherein R¹² is the novel resin bound isonitrile derivative, is advantageous over other non-resin bound isonitriles. However, use of (IXa) in the synthesis of a compound of formula (II) involves activation of the resin linker to facilitate cleavage of the resin linkage and cyclization to afford a compound of formula (II). An illustration of the use of the novel resin bound isonitrile (IXa) in the synthesis of the intermediate of the formula (XXIII) is illustrated in Scheme 9.



Scheme 9


5 The reaction conditions, and isolation of the product, of the reaction illustrated in Scheme 9 are similar to those described for the synthesis of compound of formula (XIX) illustrated in Scheme 3 above.

The benzamide compound of formula (XXIII) is then activated for nucleophilic cleavage by conversion to intermediate of formula (XXIV) under similar conditions to that described for synthesis of the intermediate of formula (XX). The conversion of (XXIII) to a compound of
10 formula (XXIV) is illustrated in Scheme 10.




Scheme 10

15 The resin "safety catch" linker is then cleaved, to facilitate the removal of the resin, by reacting the activated benzamide compound of formula (XXIV) with an appropriate alkoxide, or hydroxide, affording the corresponding alkyl esters or carboxylic acids derivative of formula (XXV) respectively, wherein R¹³ is, for example, H, alkyl, phenyl or cycloalkyl (Mjalli, A.M.M., Sarshar, S., Baiga, T.J. *Tetrahedron Lett.* 1996, 37, 2943; Flynn, D. L., Zelle, R. E., Grieco, P. A.
20 *J. Org. Chem.* 1983, 48, 2424). An example of the cleavage from the resin is illustrated in reaction Scheme 11:



Scheme 11

The intermediate compound of formula (XXV), may be converted to a compound of formula (II) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group (Z^1) and, wherein R^3 is an amine protecting group, removal of this amine protecting group also. The deprotected intermediate is then cyclized. This reaction is illustrated in Scheme 12.




Scheme 12

- 10 The reaction conditions and reagents used for the synthesis of compounds of formula (II), illustrated in Scheme 12, are similar to those described for the synthesis of compounds of formula (I) illustrated in Scheme 6.

In situations where acidic conditions are used to remove the amine protecting group in intermediate compound of formula (XXV) it may also be necessary to treat the deprotected intermediate, which is present as an acid salt, with base so as to convert the acid addition salt to its corresponding free base. There is no particular restriction on the nature of the base to be used. A base conventionally used to convert an acid addition salt to its corresponding free base form may be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include ammonia, piperidine, morpholine, ethanolamine, diethylamine, polystyrene bound di-isopropylethylamine or basic DOWEX. Preferably diethylamine, basic DOWEX or polystyrene bound di-isopropylethylamine.


General methodology for the preparation of ketopiperazines and dihydroquinoxalinone derivatives of general formula (III):-



(III)

Compounds of formula (III) may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, or by methods according to the present invention.


In general terms, compounds of formula (III) wherein n , R^1 , R^3 , R^9 , R^{10} , R^{11} , R^{14} , R^{15} and R^{16} are as hereinbefore defined, may be synthesized according to the present invention via a '3-step, 1-pot' procedure by reacting a compound of formula (XXVI) wherein R^{16} is as hereinbefore defined, with a compound of formula (XXVII) wherein n , R^3 , R^{10} , R^{11} , R^{14} and R^{15} are as hereinbefore defined and Z^1 is a suitable amine protecting group, (XV) wherein R^1 and R^9 are as hereinbefore defined, and a compound of formula (IX) wherein R^{12} is as hereinbefore defined, in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XXVIII), wherein n , R^1 , R^3 , R^9 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} , R^{16} and Z^1 are as hereinbefore defined. The general reaction is illustrated in Scheme 13 below:



Scheme 13

The reaction conditions used for the synthesis of compounds of formula (XXVIII), illustrated in Scheme 13, are similar to those described for the synthesis of compounds of formula (XVII) illustrated in Scheme 1.

The intermediate compound of formula (XXVIII) may be converted to a compound of formula (III) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group (Z^1), followed by cyclization. This reaction is illustrated in Scheme 14 below.



Scheme 14

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate

removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 14 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.


This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred.

Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).


In situations where acidic conditions are used to remove the amine protecting group in intermediate compound of formula (XXVIII) it may also be necessary to treat the deprotected intermediate, which is present as an acid salt, with base so as to convert the acid addition salt to its corresponding free base. There is no particular restriction on the nature of the base to be used. A base conventionally used to convert an acid addition salt to its corresponding free base form may be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include ammonia, piperidine, morpholine, ethanolamine, diethylamine, polystyrene bound di-isopropylethylamine or basic DOWEX. Preferably diethylamine, basic DOWEX or polystyrene bound di-isopropylethylamine.

Furthermore, a lactam intermediate of formula of formula (XXVIIIa); i.e. an intermediate of formula of formula (XXVIII) wherein R^9 and R^{16} together with the carbon atoms and nitrogen atom through which they are attached form a 5-8 membered heterocyclyl group; is formed by reacting an N-protected amine of formula of formula (XXVII) with an aldehyde-acid of formula (XXVIa) wherein r is 1, 2, 3, or 4; i.e. an aldehyde of formula (XXVI) wherein R^{16} is C-3 to C-5 alkyl substituted by an acyl group; and an isonitrile of formula (IX), under conditions analogous to those described for synthesizing intermediate (XXVIII) in scheme 1. This reaction is illustrated in Scheme 13a.



Scheme 13a


The lactam intermediate of formula (XXVIIIa) can then undergo further cyclisation to afford compounds of formula (IIIa) i.e. compounds of formula III, wherein R^9 and R^{16} together with the carbon atoms and nitrogen atom through which they are attached form a 5-8 membered heterocyclyl group. This reaction is illustrated in Scheme 13b. The cyclisation of the lactam intermediate of formula (XXVIIIa) to afford the compound of formula (IIIa) wherein r is 1, 2, 3, or 4, is carried out under conditions analogous to those described for synthesizing compound of formula (II) in scheme 14 above.



Scheme 13b

The use of the novel resin bound isonitrile (IXa) in the synthesis of intermediate compounds of the formula (XXVIII) wherein R^{12} is a novel resin bound isonitrile derivative (IXa) is advantageous over other non-resin bound isonitriles. However, use of an isonitrile of formula (IXa) in the synthesis of compounds of formula (III) involves activation of the resin linker to facilitate cleavage of the resin linkage and cyclization to afford a compound of formula


(III). An illustration of the use of the novel resin bound isonitrile of formula (IXa) in the synthesis of the intermediate of formula (XXIX) is illustrated in Scheme 15 below.



Scheme 15


The reaction conditions, and isolation of the product, of the reaction illustrated in Scheme 15 are similar to those described for the synthesis of compound of formula (XIX) illustrated in Scheme 3 above.

The benzamide compound of formula (XXIX) is then activated for nucleophilic cleavage by conversion to intermediate of formula (XXX) under similar conditions to that described for synthesis of the intermediate of formula (XX). The conversion of a compound of formula (XXIX) to a compound of formula (XXX) is illustrated in Scheme 16.




Scheme 16

The resin "safety catch" linker is then cleaved, to facilitate the removal of the resin, by reacting the activated benzamide compound of formula (XXX) with an appropriate alkoxide, or hydroxide, affording the corresponding alkyl esters or carboxylic acids derivative of formula (XXXI) respectively, by the same procedure as described for the synthesis of compounds of formula (XXV) above. An example of the cleavage from the resin is illustrated in reaction Scheme 17:



Scheme 17

5 The intermediate compound of formula (XXXI), may be converted to a compound of formula (III) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group (Z^1) and, wherein R^3 is an amine protecting group, removal of this amine protecting group also. The deprotected intermediate is then cyclized to afford the product of formula (III). This reaction is illustrated in Scheme 18.




Scheme 18

15 The reaction conditions and reagents used for the synthesis of compounds of formula (III), illustrated in Scheme 18, are similar to those described for the synthesis of compounds of formula (I) illustrated in Scheme 6.

20 In situations where acidic conditions are used to remove the amine protecting group in intermediate compound of formula (XXXI) it may also be necessary to treat the deprotected intermediate, which is present as an acid salt, with base so as to convert the acid addition salt to its corresponding free base. There is no particular restriction on the nature of the base to be used. A base conventionally used to convert an acid addition salt to its corresponding free base form may be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include ammonia, piperidine, morpholine, ethanolamine, diethylamine, polystyrene bound di-isopropylethylamine or basic DOWEX. Preferably diethylamine, basic DOWEX or polystyrene bound di-isopropylethylamine.

25 The use of the resin bound isonitrile of formula (XVIII) in the synthesis of compounds of the formula (XXXII), wherein R^{12} -NC is the resin bound isonitrile derivative of formula (XVIII), is advantageous over other non-resin bound isonitriles. However, use of an isonitrile of formula (IXa) in the synthesis of compounds of formula (III) involves activation of the resin linker to facilitate cleavage of the resin linkage and cyclization to afford a compound of formula (III). An


illustration of the use of the novel resin bound isonitrile of formula (XVIII) in the synthesis of the intermediate of the formula (XXXII) is illustrated in Scheme 19.



Scheme 19

The reaction conditions used for the synthesis of compounds of formula (XXXII), illustrated in Scheme 19, are similar to those described for the synthesis of compounds of formula (XVII) illustrated in Scheme 1.

The intermediate compound of formula (XXXII) may be converted to a compound of formula (III) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in Scheme 20.



Scheme 20

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 20 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base


conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

5 This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the
10 nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.


There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred.
15 Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

In situations where acidic conditions are used to remove the amine protecting group in
20 intermediate compound of formula (XXXII) it may also be necessary to treat the deprotected intermediate, which is present as an acid salt, with base so as to convert the acid addition salt to its corresponding free base. There is no particular restriction on the nature of the base to be used. A base conventionally used to convert an acid addition salt to its corresponding free base form may be used here, provided that it has no adverse effect on other parts of the molecule. Examples
25 of suitable bases include ammonia, piperidine, morpholine, ethanolamine, diethylamine, polystyrene bound di-isopropylethylamine or basic DOWEX. Preferably diethylamine, basic DOWEX or polystyrene bound di-isopropylethylamine.

30 General methodology for the preparation of
dihydroimidazole derivatives of general formula (IV)



In general terms, compounds of formula (IV) wherein R^2 , R^9 , R^{10} , R^{11} , R^{12} and R^{16} are as hereinbefore defined, may be synthesized according to the present invention via a '3-step, 1-pot' procedure by reacting a compound of formula (XXVI) wherein R^{16} is as hereinbefore defined with compound of formula (XXXIII) wherein R^9 , R^{10} and R^{11} are as hereinbefore defined and Z^1 is a amine protecting group, (IX) wherein R^{12} is as hereinbefore defined, and (XVI) wherein R^2 is as hereinbefore defined, in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XXXIV), wherein R^2 , R^9 , R^{10} , R^{11} , R^{12} , Z^1 and R^{16} , are as hereinbefore. The general reaction is illustrated in scheme 21 below:



Scheme 21

The conversion of the compound of formula (XXXIV) to the compound of formula IV is described hereinafter with reference to Scheme 22. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved (See Waki et al. J. Am. Chem. Soc., 1977, 6075-6077, the contents of which are hereby incorporated herein by reference). Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, and hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, and dimethylformamide; halides, such as dichloromethane, and dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.


There is no restriction on the isonitrile used in the reaction scheme 21 above. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isocyanides include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the

nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of the formula (XXXIV) thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling off the solvent in vacuo from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography. The intermediate compound is preferably recovered from the reaction mixture by distilling off the solvent in vacuo.

The intermediate compound of formula (XXXIV) may be converted to a compound of formula (IV) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 22.



Scheme 22

Cyclization of the deprotected amine to dihydroimidazole proceeded an average of 66% of possible dihydroimidazole product. The remaining no-cyclized amines are removed via a solution phase scavenging step with the simultaneous addition of PS-DIEA or PS-tris(2-aminoethyl)amine (6 equiv.) and PS-NCO (3 equiv.) in dichloroethane. (Booth, R.J.; Hodges, J.C. *J. Am. Chem. Soc.* 1997, 119, 4882. Flynn, D.L.; Crich, J. Z.; Devraj, R. V.; Hockerman, S.L.; Parlow, J.J.; South, M.S.; Woodward, S. *J. Am. Chem. Soc.* 1997, 119, 4874. Purchased from Argonaut[®] technologies (PS-DIEA - polystyrene bound diisopropylethylamine)).

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z¹ and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.


In addition to carrying out the reaction in scheme 22 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C , preferably from room temperature to about 100°C , more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

There is no particular restriction on the amine protecting group (Z^1) employed. However, acid labile amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC).

It is also envisaged that a solid phase synthesis of compounds of formula (IV) could be carried out using a resin bound Ugi component of formulae (XII), (IXa), (XV) or (XXXIII) using similar reaction conditions as described herein.

General methodology for the preparation of lactam derivatives of general formula (V)




(V)

In general terms, compounds of formula (V) wherein p , R^2 , R^3 , R^9 , R^{14} , R^{15} and R^{16} are as hereinbefore defined, may be synthesized according to the present invention via a '3-step, 1-pot' procedure by reacting a compound of formula (XXVI) wherein R^{16} is as hereinbefore defined, with a compound of formula (XXXV) wherein p , R^3 , R^9 , R^{14} , R^{15} and Z^1 are as hereinbefore

defined, an amine of formula (XVI) wherein R^2 is as hereinbefore defined, and a resin bound isonitrile of formula (XVIII) in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XXXVI), wherein p , R^2 , R^3 , R^9 , R^{14} , R^{15} , R^{16} and Z^1 are as hereinbefore defined. The general reaction is illustrated in Scheme 23 below:

5




Scheme 23

The conversion of the compound of formula (XXXVI) to the compound of formula V is described hereinafter with reference to Scheme 24. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved (See Waki et al. J. Am. Chem. Soc., 1977, 6075-6077, the contents of which are hereby incorporated herein by reference). Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, and hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, and dimethylformamide; halides, such as dichloromethane, and dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C , preferably from room temperature to about 100°C , more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of formula (XXXVI) may be converted to a compound of formula (V) by reacting with acid or base, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 24 below:

30



Scheme 24


This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C , preferably from room temperature to about 100°C , more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.


There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting groups include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting groups include 9-fluorenylmethyl carbamate (Fmoc).

Similarly, the synthesis of compounds of formula (V) can be carried out in solid phase using a resin bound isonitrile of formula (IXa) and using reaction conditions similar to those described for schemes 15-18.

Alternatively, the synthesis of compounds of formula (V) can be carried out in solution phase using a non resin bound isonitrile.



In general terms, compounds of formula (VI) wherein m , R^1 , R^2 , R^3 , R^{10} , R^{11} , R^{12} , R^{14} and R^{15} are hereinbefore defined, may be synthesized by reacting a compound of formula (XIV) wherein m , R^3 , R^{10} , R^{11} , R^{14} and R^{15} are hereinbefore defined and Z^1 is a suitable amine protecting group, with compound of formula (XXXVII) wherein R^1 and R^9 are hereinbefore defined, a compound of formula (XVI) wherein R^2 is hereinbefore defined, and an isonitrile of formula (IX) wherein R^{12} represents hydrogen, alkyl, aroyl, aralkyl, aryl, fused arylcycloalkyl, fused arylheterocyclyl, cycloalkyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclyl, heterocyclyl; in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XXXVIII) wherein m , R^1 , R^2 , R^3 , R^9 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} , and Z^1 are hereinbefore defined. The general reaction is illustrated in scheme 25 below:



The conversion of the compound of formula (XXXVIII) to the compound of formula VI is described hereinafter with reference to Scheme 26. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved (See Waki et al. J. Am. Chem. Soc., 1977, 6075-6077, the contents of which are hereby incorporated herein by reference). Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, and hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, and dimethylformamide; halides, such as dichloromethane, and dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite,


tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

There is no restriction on the isonitrile (R^{12} -NC) used in the reaction scheme above, provided that it has no adverse effect on the reaction involved. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isocyanides include cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of the formula (XXXVIII) thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling off the solvent in vacuo from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography. The intermediate compound is preferably recovered from the reaction mixture by distilling off the solvent in vacuo.

The intermediate compound of formula (XXXVIII) may be converted to a compound of formula (VI) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 26.



Scheme 26


This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 26 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (FMOC).


General methodology for the preparation of 1,4-benzodiazepine-2,5-dione derivatives of general formula (VII)



(VII)

Compounds of formula (VII) may be synthesized according to the present invention via a '3-step, 1-pot' procedure by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, or by methods according to the present invention.

In general terms, compounds of formula (VII) wherein R^1 , R^3 , $R^{8'}$, R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} are hereinbefore defined, and Z^1 is a suitable amine protecting group, may be synthesized by reacting an isonitrile compound of formula (IX), wherein R^{12} , is hereinbefore defined, with compound of formula (XV) wherein R^1 and R^9 are hereinbefore defined, a compound of formula (XIV) wherein R^3 , $R^{8'}$, R^6 , R^7 and R^8 are hereinbefore defined and resin bound amino ester compound of formula (XXXIX) wherein R^{10} , R^{11} are as hereinbefore defined, R^{17} and R^{18} independently represent hydrogen, alkyl, aralkyl, aryl, fused arylcycloalkyl, fused arylheterocyclyl, aryloxy, cycloalkyl, heteroaralkyl, heteroaryl, fused heteroaryl-cycloalkyl, fused heteroarylheterocyclyl, or heterocyclyl, most preferably, alkyl or hydrogen; and q is 1, 2 or 3, in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XL). This reaction is illustrated in scheme 27 below:



Scheme 27


There is no restriction on the isonitrile used in the reaction scheme 27 above. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isonitriles include

benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate. More preferably is 1-isocyanocyclohexene.

There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, dimethylformamide; halides, such as dichloromethane, dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of formula (XL) may be converted to a compound of formula (VII) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 28 below:



Scheme 28

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z¹ and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by

the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.


In addition to carrying out the reaction in scheme 28 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

Alternatively, the synthesis of compounds of formula (VII) can be carried out in solution phase using a non resin bound amino ester.


General methodology for the preparation of Ketopiperazine and Dihydroquinoxalinone derivatives of general formula (VIII)



(VIII)

In general terms, compounds of formula (VIII) wherein n , R^1 , R^3 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} and R^{16} are hereinbefore defined, may be synthesized according to the present invention via a '3-step, 1-pot' procedure by reacting a compound of formula (XXVI) wherein R^{16} is hereinbefore defined,

with a compound of formula (XXVII) wherein n , R^3 , R^{10} , R^{11} , R^{14} and R^{15} are hereinbefore defined and Z^1 is a suitable amine protecting group, a compound of formula (XXXVII) wherein R^1 and R^9 are hereinbefore defined, and an isonitrile of formula (IX) wherein R^{12} is hereinbefore defined, in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XLI), wherein n , R^1 , R^3 , R^9 , R^{10} , R^{11} , R^{14} , R^{15} , R^{16} and Z^1 are hereinbefore defined. The general reaction is illustrated in Scheme 29 below:



Scheme 29

It is known that when the nucleophilicity of the nitrogen atom adjacent to R^{10} and R^{11} is poor, the Passerini reaction (See J. March, Advanced Organic Chemistry, 3rd Ed., John Wiley & Sons p. 870-871 (1985)) predominates and the yields of the desired cyclized product of formula (VIII) is lowered. Therefore, it is preferred that at least one of R^{10} and R^{11} is an electron donating group, or when $n=1$, and R^{11} and R^{14} are absent and R^{10} and R^{15} taken together with the adjacent carbon atoms through which they are linked form an electron donating 6 membered aryl or 5 to 6 membered an electron donating heteroaryl; or when $n=1$, R^{10} and R^{15} taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered an electron donating cycloalkyl group or an electron donating heterocyclyl group; or when $n=2$, and adjacent R^{11} and R^{14} are absent, R^{10} and adjacent R^{15} taken together with the adjacent carbon atoms through which they are linked form a 6 membered electron donating aryl group or 5 to 6 membered electron donating heteroaryl group; or when $n=2$, R^{10} and adjacent R^{15} taken together with the adjacent carbon atoms through which they are linked form a 5 to 7 membered electron donating cycloalkyl group or an electron donating heterocyclyl group; so as to increase the nucleophilicity of the adjacent nitrogen atom and give higher yields of the desired product of formula (VIII).

There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved (See Waki et al. J. Am. Chem. Soc., 1977, 6075-6077, the contents of which are hereby incorporated herein by reference). Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, and hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, and dimethylformamide; halides, such as dichloromethane, and dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include


water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

There is no restriction on the isonitrile (R^{12} -NC) used in the reaction scheme above, provided that it has no adverse effect on the reaction involved. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isonitriles include cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of the formula (XLI) thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling off the solvent in vacuo from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography. The intermediate compound is preferably recovered from the reaction mixture by distilling off the solvent in vacuo.

The intermediate compound of formula (XLI) may be converted to a compound of formula (VIII) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 30.



Scheme 30


This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 30 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).


Alternatively, a compound of the formula (VIII) wherein n , R^1 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} and R^{16} are hereinbefore defined and R^3 is hydrogen, may be prepared by '2-step, one pot' method by reacting a compound of formula (XXVI) wherein R^{16} is hereinbefore defined, with a compound of formula (XXVIIa) wherein n , R^{10} , R^{11} , R^{14} and R^{15} are hereinbefore defined and R^3 is hydrogen, a compound of formula (XXXVII) wherein R^1 and R^9 are hereinbefore defined, and an isonitrile of formula (IX) wherein R^{12} is hereinbefore defined, in a suitable solvent and appropriate temperature to effect cyclization and afford a compound of formula (VIII). The general reaction is illustrated in Scheme 31 below:



Scheme 31

The solvent and isonitrile used in this reaction are similar to those used for the synthesis of a compound of formula (XLI) illustrated in Scheme 30. The reaction temperature used in this reaction is similar to that used for the cyclization of a compound of formula (XLI) illustrated in Scheme 30. It would also be understood by a skilled person in the art that use of a diamino compound of formula (XXVIIa) wherein R¹⁰, R¹¹, R¹⁴ and R¹⁵ are identical to each other would produce a single compound of formula (VIII).


General methodology for the preparation of ketopiperazine derivatives
of general formula (XLII)



Compounds of formula (XLII) may be synthesized according to the present invention via a '3-step, 1-pot' procedure by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, or by methods according to the present invention.

In general terms, compounds of formula (XLII) wherein R³, R⁴, R⁵, R⁹, R¹⁰, R¹¹, R¹² and R¹⁶, are hereinbefore defined, may be synthesized by reacting an isonitrile compound of formula (IX), wherein R¹², is hereinbefore defined, with compounds of formula (XLIII) wherein R³, R⁴, R⁵, R⁹ and Z¹ are hereinbefore defined, a compound of formula (XXVI) wherein R¹⁶ is hereinbefore defined and amino ester bound resin compound of formula (XXXIX) wherein R¹⁰, R¹¹ are as hereinbefore defined, R¹⁷ and R¹⁸ independently represent hydrogen, alkoxycarbonyl, alkyl, aralkoxycarbonyl, aralkyl, aroyl, aryl, fused arylcycloalkyl, fused arylheterocyclyl, aryloxy, aryloxy carbonyl, cycloalkyl, heteroaralkyl, heteroaroyl, heteroaryl, fused heteroaryl cycloalkyl,

fused heteroarylheterocyclyl, or heterocyclyl; and q is 1, 2 or 3, in a suitable solvent at about room temperature, to afford the intermediate compound of formula (XLIX). This reaction is illustrated in scheme 32 below:




Scheme 32

There is no restriction on the isonitrile used in the reaction scheme 32 above. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isonitriles include benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate. More preferred is 1-isocyanocyclohexene.

There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene ; amides, such as dimethyl acetamide, dimethylformamide; halides, such as dichloromethane, dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of formula (XLIX) may be converted to a compound of formula (XLII) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 33 below:



Scheme 33

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z¹ and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 33 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z¹, wherein Z¹ is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z¹, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.


There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl

(BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

Similarly, the synthesis of compounds of formula (XLII) can be carried out in solution phase using a non resin bound amino ester.

5

General methodology for the preparation of cyclic ureas derivatives
of general formula (L)



10


(L)

Compounds of formula (L) may be synthesized according to the present invention via a '3-step, 1-pot' procedure by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, or by methods according to the present invention.

15

In general terms, compounds of formula (L) wherein R^1 , R^3 , R^9 , R^{10} , R^{11} , R^{12} , R^{14} and R^{15} are hereinbefore defined and n is 1 or 2, may be synthesized by generating the acid of formula (LI) in situ (by bubbling CO_2 through methanol at 0°C for 5 minutes), reacting the acid of formula (LI) with an isonitrile compound of formula (IX), wherein R^{12} , is hereinbefore defined, with compounds of formula (XXVII) wherein R^3 , R^{10} , R^{11} , R^{14} , R^{15} , Z^1 and n are hereinbefore defined, and with an aldehyde or ketone of formula (XV) wherein R^1 , R^9 are as hereinbefore defined; and n is 1 or 2, in a suitable solvent at about room temperature, to afford the intermediate compound of formula (LII). This reaction is illustrated in scheme (34) below:

20



25


Scheme (34)

There is no restriction on the isonitrile used in the reaction scheme 34 above. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isonitriles include benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate. More preferred is 1-isocyanocyclohexene.

There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, dimethylformamide; halides, such as dichloromethane, dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of formula (LII) may be converted to a compound of formula (L) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 35 below:



Scheme 35

This reaction is carried out in the presence of an acid. There is no particular restriction on the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z¹ and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids

include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

5 In addition to carrying out the reaction in scheme 35 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may
10 equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.


This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the
15 reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

20 There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl
25 (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

Alternatively, the synthesis of compounds of formula (L) can be carried out in solid phase using a resin bound isonitrile, for example, isonitrile functionalized polymer resin (IXa), 1-isocyanocyclohexene (IXb), or (XVIII).


30

General methodology for the preparation of cyclic urea derivatives
of general formula (LIII)



Compounds of formula (LIII) may be synthesized according to the present invention via a '3-step, 1-pot' procedure by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, or by methods according to the present invention.

In general terms, compounds of formula (LIII) wherein R^2 , R^9 , R^{10} , R^{11} and R^{12} , are hereinbefore defined and q is 1 or 2, may be synthesized by generating the acid of formula (LI) in situ (by reacting CO_2 in the presence of methanol (CO_2 is bubbled through the reaction solution for 5 minutes at $0^\circ C$), reacting the acid of formula (LI) with an isonitrile compound of formula (IX), wherein R^{12} , is hereinbefore defined, an aldehyde or ketone of formula (XXXIII) wherein R^9 , R^{10} , R^{11} , Z^1 and q are hereinbefore defined, and an amine of formula (XVI) wherein R^2 , is as hereinbefore defined; in a suitable solvent at about room temperature, to afford the intermediate compound (LIV). This reaction is illustrated in scheme 36 below:



There is no restriction on the isonitrile used in the reaction scheme 36 above. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isonitriles include benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate. More preferred is 1-isocyanocyclohexene.


There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide,

dimethylformamide; halides, such as dichloromethane, dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulfoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

5 The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the
10 nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound (LIV) may be converted to a compound of formula (LIII) by reacting with acid, in a suitable solvent and appropriate temperature, to effect removal of the amine protecting group, followed by cyclization. This reaction is illustrated in scheme 37 below:

15



Scheme 37

This reaction is carried out in the presence of an acid. There is no particular restriction on
20 the nature of the acid to be used in this reaction, and any acid conventionally used to facilitate removal of an acid labile amine protecting group Z^1 and cyclization, may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable acids include: mineral acids such as hydrochloric acid or sulfuric acid; organic acids such as trifluoroacetic acid. Acids to be used in the reaction can also be generated in situ, for example by
25 the addition of acetyl chloride in methanol, to generate hydrochloric acid. Preferably, anhydrous acids are used.

In addition to carrying out the reaction in scheme 37 in the presence of acid, a reaction step involving basic conditions can also be optionally carried out so as to facilitate the removal of the amine protecting group Z^1 , wherein Z^1 is a base labile amine protecting group. There is no
30 particular restriction on the nature of the base to be used in this reaction, and any base conventionally used to facilitate removal of an base labile amine protecting group Z^1 , may equally be used here, provided that it has no adverse effect on other parts of the molecule.


Examples of suitable bases include: organic bases such as ammonia, piperidine, morpholine, ethanolamine and diethylamine.

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

There is no particular restriction on the amine protecting group (Z^1) employed. However, amine protecting groups which allow removal of the protecting group and cyclization of the deprotected intermediate, without purification or isolation of intermediates, are preferred. Examples of amine protecting groups include both acid labile amine protecting groups and base labile protecting groups. Preferred acid labile amine protecting group include *tert*-butoxycarbonyl (BOC) and 2-(4-biphenyl)-isopropoxy carbonyl (BPOC). Preferred base labile amine protecting group include 9-fluorenylmethyl carbamate (Fmoc).

Similarly, the synthesis of compounds of formula (LVIII) can be carried out in solid phase using a resin bound isonitrile(R^{12} -NC), for example, isonitrile functionalized polymer resin (IXa), 1-isocyanocyclohexene (IXb), or (XVIII).


General methodology for the preparation of hydantoin derivatives
of general formula (LV)



Compounds of formula (LV) may be synthesized according to the present invention via a '3-step, 1-pot' procedure by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, or by methods according to the present invention.

In general terms, hydantoin compounds of formula (LV) wherein R^1 , R^2 , R^9 , and R^{12} , are hereinbefore defined, may be synthesized by generating the acid of formula (LI) in situ (CO_2 is bubbled through the reaction solution for 5 minutes at 0°C), reacting the acid of formula (LI) with an isonitrile compound of formula (IX), wherein R^{12} , is hereinbefore defined, with compounds of

formula (XV) wherein R^1 and R^9 are hereinbefore defined, an amine of formula (XVI) wherein R^2 is as hereinbefore defined; in a suitable solvent at about room temperature, to afford the intermediate compound (LVI). This reaction is illustrated in scheme 38 below:




Scheme 38

There is no restriction on the isonitrile used in the reaction scheme 38 above. Examples of suitable isonitriles include, benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate, cyclohexyl isocyanide, 2,6-dimethylphenyl isocyanide, methyl isocyanoacetate, isopropyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide. Preferable isonitriles include benzyl isocyanide, n-butyl isocyanide, diethyl isocyanomethyl phosphonate. More preferred is 1-isocyanocyclohexene.

There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: alcohols, such as methanol, 1-butanol, phenol, trifluoroethanol, hexafluoro-2-propanol; hydrocarbons, such as benzene and toluene; amides, such as dimethyl acetamide, dimethylformamide; halides, such as dichloromethane, dichloroethane; and ethers, such as tetrahydrofuran and dioxane; other solvents include water, 1-methyl-2-pyrrolidine, diethyl phosphite, tetramethylsulphone, dimethyl sulphoxide, acetonitrile and pyridine. Of these solvents, the alcohols are preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

The intermediate compound of formula (LVI) may be converted to a compound of formula (LV) by heating in a suitable solvent, to effect cyclization. This reaction is illustrated in scheme 39 below:



Scheme 39

This reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from about 0°C to about 150°C, preferably from room temperature to about 100°C, more preferably at about room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 36 hours will usually suffice.

Alternatively, the synthesis of compounds of formula (LV) can be carried out in solid phase using a resin bound isonitrile(R¹²-NC), for example, isonitrile functionalized polymer resin of formula (IXa), 1-isocyanocyclohexene of formula (IXb), or isonitrile functionalized polymer resin of formula (XVIII).

According to a further feature of the present invention, compounds of the invention may be prepared by interconversion of other compounds of the invention.

A compound of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (XLII), (L) (LIII), and (LV) including a group containing one or more nitrogen ring atoms, preferably imine (=N-), may be converted to the corresponding compound wherein one or more nitrogen ring atom of the group is oxidized to an N-oxide, preferably by reacting with a peracid, for example peracetic acid in acetic acid or m-chloroperoxybenzoic acid in an inert solvent such as dichloromethane, at a temperature from about room temperature to reflux, preferably at elevated temperature.

As an example of the interconversion process, compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (XLII), (L) (LIII), and (LV), containing sulfoxide linkages may be prepared by the oxidation of corresponding compounds containing -S- linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulphate in a medium such as aqueous methanol, buffered to about pH 5, at temperatures between about 0°C and room temperature. This latter method is preferred for compounds containing an acid-labile group.

As another example of the interconversion process, compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (XLII), (L) (LIII), and (LV) containing sulphone linkages may be prepared by the oxidation of corresponding compounds containing -S- or sulfoxide linkages.

For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferred is in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.

5 It will be understood that designation of aromaticity with respect to carbocycles and heterocycles herein includes any highly resonant unsaturated ring structure. Alternatively, placement of double bonds, where indicated, represents one potential structure for the depicted compound but will be understood to include other resonant states of the compound as well as protonated and charged species, only one of which may be shown.

10 It will be appreciated that compounds of the present invention may contain asymmetric centers. These asymmetric centers may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (XII), (L) (LIII),
15 and (LV), hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallization techniques, or they are separately prepared from the appropriate isomers of their intermediates.

For the propose herein it is understood that tautomer forms are included in the recitation of a given group, e.g., thio/mercapto or oxo/hydroxyl.

20 Acid additional salts are formed with the compounds of the invention in which a basic function such as an amino, alkylamino, or dialkylamino group is present. The pharmaceutically acceptable, i.e., nontoxic, acid addition salts are preferred. The salts chosen are chosen optimally to be compatible with the customary pharmaceutical vehicles and adapted for oral or parenteral administration. Acid addition salts of the compounds of this invention may be prepared by
25 reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or
30 can be obtained by concentration of the solution. Some suitable acids for use in the preparation of such salts are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, various organic carboxylic and sulfonic acids, such as acetic acid, citric acid, propionic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methanesulfonic acid, toluenesulfonic acid, fatty acids, adipate, alginate, ascorbate, aspartate,
35 benzenesulfonate, benzoate, cyclopentanepropionate, digluconate, dodecylsulfate, bisulfate, butyrate, lactate, laurate, lauryl sulfate, malate, hydroiodide, 2-hydroxy-ethanesulfonate, glycerophosphate, picrate, pivalate, pamoate, pectinate, persulfate, 3-phenylpropionate,

thiocyanate, 2-naphthalenesulfonate, undecanoate, nicotinate, hemisulfate, heptonate, hexanoate, camphorate, camphersulfonate, and others.

The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Base addition salts may be formed where the compound of the invention contains a carboxy group, or a sufficiently acidic bioisostere. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like.

Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.

EXAMPLE 1


Solution Phase Synthesis of Compounds of Formula (I) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:

Equal amounts (0.1 ml) of 0.1 M solutions of the four appropriate components compound of formulae (XIV), (XV), (XVI) and (IXb), are employed generating a theoretical 10 μ mol of final 1,4-benzodiazepine-2,5-dione product (I) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 °C (using a SAVANT® evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in

dichloroethane. Solvents are then evaporated at 65 °C to afford the cyclized product compound of formula (I). Lc/ms analysis (liquid chromatography/mass spectrometry) is performed using a C18 Hypersil BDS 3m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 10% to 100% 15 min, at a rate of 1ml/min. Desired products are seen as (M+ 1).

5

Table 5 below shows the lc/ms A% yields taken from two 96 well plates using the experimental procedure described above and the Ugi components listed as 1-22 below:



10

Table 1 contains hplc retention times of the desired products from anthranilic acid 1 using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA in H₂O/CH₃CN 10% to 100%, 5 min, at a rate of 1ml/min. For example, Table 1 indicates that anthranilic acid 1 reacted with amine 3 and aldehyde 15 affords the desired product with a retention time of 3.78, under the conditions mentioned above.

15

TABLE 1

	3	4	5	6	7	8	9	10	11	12	13	14
15	3.78	3.92	4.18	3.79	3.52	4.14	2.82	3.26	4.63	2.86	4.36	3.04
16	4.71	4.84	5.15	4.67	4.58	4.97	3.70	4.14	5.46	3.61	5.15	4.01
17	4.31	4.40	4.67	4.27	4.14	4.58	3.35	3.79	5.02	3.30	4.75	3.61
18	3.61	3.79	4.05	3.65	3.35	4.01	2.55	3.04	4.53	2.46	4.27	2.82
19	4.01	4.14	4.01	4.01	3.83	4.36	3.04	3.48	4.80	4.58	3.26	4.27
20	4.27	4.40	4.62	4.27	4.14	4.53	3.04	3.83	4.97	3.43	4.75	3.65
21	5.11	5.20	5.50	5.02	4.97	5.33	4.05	4.49	5.86	3.92	5.55	4.36
22	3.43	3.74	3.91	3.48	3.34	3.87	2.64	3.08	4.31	2.95	4.18	2.86

Table 2 contains the molecular weight of the desired products from anthranilic acid 1. Desired products are seen as (M+ 1). For example, Table 2 indicates that anthranilic acid 1 reacted with

amine 3 and aldehyde 15 affords the desired product with a molecule weight (M+1) of 308.4, under the conditions mentioned above.

TABLE 2

	3	4	5	6	7	8	9	10	11	12	13	14
15	308.4	322.4	302.4	338.4	274.4	336.4	326.4	401.5	364.5	345.4	398.5	343.4
16	350.5	364.5	344.5	380.5	316.4	378.5	368.5	443.6	406.6	387.5	440.6	385.5
17	370.5	384.5	364.5	400.5	336.4	398.5	388.5	463.6	426.6	407.5	460.6	405.5
18	294.4	308.4	288.4	324.4	260.3	322.4	312.4	387.5	350.5	331.4	384.5	329.4
19	322.4	336.4	316.4	352.4	288.4	350.5	340.4	415.5	378.5	359.4	412.5	357.5
20	428.5	442.5	422.5	458.5	394.5	456.5	446.5	521.6	484.6	465.5	518.6	463.5
21	390.5	404.6	384.6	420.6	356.5	418.6	408.5	483.6	446.6	427.6	480.7	425.6
22	378.4	392.5	372.5	408.5	344.4	406.5	396.4	471.5	434.5	415.5	468.6	413.5

- 5 Table 3 contains hplc retention times of the desired products from anthranilic acid 2. For example, Table 3 indicates that anthranilic acid 2 reacted with amine 3 and aldehyde 15 affords the desired product with a retention time of 4.01, under the conditions mentioned above.

TABLE 3

	3	4	5	6	7	8	9	10	11	12	13	14
15	4.01	4.09	4.45	4.01	3.79	4.36	2.95	3.30	4.84	-	4.62	2.95
16	4.97	5.15	5.46	4.89	4.93	5.28	3.87	4.36	5.68	3.92	5.46	4.27
17	4.49	4.67	4.93	4.49	4.45	4.84	3.52	3.96	5.24	3.57	5.02	3.83
18	3.83	4.05	4.36	3.83	3.61	4.27	2.73	3.26	4.75	2.91	4.49	3.04
19	4.23	4.36	4.67	4.23	4.05	4.58	3.17	3.56	5.06	-	4.80	3.48
20	4.36	4.62	4.84	4.36	4.40	4.71	3.43	3.92	5.06	-	4.97	3.70
21	5.28	5.46	5.81	5.20	5.28	5.59	4.18	4.67	6.03	3.83	5.50	4.62
22	3.61	3.96	4.23	3.79	3.57	4.14	2.77	3.26	4.39	2.51	4.40	3.04

10

Table 4 contains molecular weight of the desired products from anthranilic acid 2. Desired products are seen as (M+ 1). For example, Table 4 indicates that anthranilic acid 2 reacted with amine 3 and aldehyde 15 affords the desired product with a molecule weight (M+1) of 322.4, under the conditions mentioned above.

15

TABLE 4

	3	4	5	6	7	8	9	10	11	12	13	14
15	322.4	336.4	316.4	352.4	288.4	350.5	340.4	415.5	378.5	359.4	412.5	357.5
16	364.5	378.5	358.5	394.5	330.5	392.5	382.5	457.6	420.6	401.5	454.6	399.5

17	384.5	398.5	378.5	414.5	350.5	412.5	402.5	477.6	440.6	421.5	474.6	419.5
18	308.4	322.4	302.4	338.4	274.4	336.4	326.4	401.5	364.5	345.4	398.5	343.4
19	336.4	350.5	330.5	366.5	302.4	364.5	354.5	429.5	392.5	373.5	426.5	371.5
20	442.5	456.5	436.5	472.5	408.5	470.6	460.5	535.6	498.6	479.5	532.6	477.6
21	404.6	418.6	398.6	434.6	370.5	432.6	422.6	497.7	460.7	441.6	494.7	439.6
22	392.5	406.5	386.5	422.5	358.4	420.5	410.5	485.6	448.6	429.5	482.6	427.5

Table 5, Note: For A% yields x/y : The first yield "x" represents that for reactions with *N*-BOC anthranilic acid, 1. The second yield "y" represents that for *N*-Me-BOC anthranilic acid, 2. Row 15 represents yields of reactions with aldehyde 15. Column 3 represents yields of reactions with amine 3. For example, Table 5 indicates that anthranilic acid 1 reacted with amine 3 and aldehyde 15 affords the desired product with a yield 40%, under the conditions mentioned above.

TABLE 5


	3	4	5	6	7	8	9	10	11	12	13	14
15	40/16	40/29	40/27	54/15	40/25	39/40	26/16	18/21	41/15	1/0	39/31	47/30
16	85/87	82/72	77/64	79/72	82/69	84/67	81/73	78/67	82/74	43/10	88/74	84/73
17	88/84	85/73	89/68	92/81	92/78	88/68	90/75	82/73	84/79	39/8	76/77	85/72
18	87/80	72/52	69/43	79/70	70/41	80/51	87/63	81/64	81/70	51/25	75/60	80/62
19	45/10	37/24	39/22	36/12	34/20	33/12	41/7	28/26	44/10	9/0	37/16	39/20
20	79/49	74/61	63/51	75/12	66/53	69/54	59/10	74/61	83/67	6/0	71/49	67/64
21	89/87	86/69	88/66	85/82	89/63	85/70	90/74	83/69	86/84	38/8	84/74	88/78
22	85/64	86/63	80/67	85/82	84/75	85/64	82/69	84/67	86/75	27/11	84/69	83/61

10 EXAMPLE 2

General Solid Phase Synthesis of Compounds of Formula (I) using the Ugi reaction and resin (IXa)

(60mg) of resin (IXa) is pre-swelled with THF. 0.5M solutions of the appropriate aldehyde (XV) (10 equiv.), amine (XVI) (10 equiv.) and carboxylic acid (XIV) (10 equiv.) in THF:MeOH (1:1) are added sequentially to the resin (IXa) and the reaction stirred at room temperature for 3 days. The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi product (IXa) Treatment with BOC₂O (10 equiv.), Et₃N (10 equiv.) and DMAP in CH₂Cl₂ (15 hours) afforded the activated resin (XX) for cleavage. Sodium methoxide (5mg) in THF: MeOH, 1:1, is added to the resin and shaken for 20 hours. The solvent is evaporated in vacuo to give the desired methyl ester (XXI). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of

trifluoroacetic acid in dichloroethane. The samples are then evaporated in a SAVANT at room temperature for 3 hours to give the crude product of formula (I). Examples of products (examples 23 to 28) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a Hypersil BDS 3 m C18 4.6X50mm 0.1%TFA in H₂O/CH₃N 10% to 100% CH₃N 5 min, at a rate of 1ml/min for 23-28. Desired products are seen as (M+ 1).



Compound	Retention time	mass spec	ELSD A%	UV (220 nm) A%
23	3.36	388	>90	>90
24	3.62	402	90	>90
25	3.93	338	90	80
26	4.27	288	90	91
27	6.48	400	95	91
28	4.36	336	89	80

EXAMPLE 3

Solution Phase Synthesis of Compounds of Formula (II) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:

Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components compound of formulae (XXII), (XV), (XVI) and (IXb), are employed generating a theoretical 10 μ mol of final diketopiperazine product (II) for 100% conversion. The 4-component condensation is performed

in methanol at room temperature and the solvent evaporated at 65 °C (using a SAVANT® evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and a 5% solution of diethylamine in dichloroethane [Note : 10-15 mg of N,N-(diisopropyl)amino-methylpolystyrene (PS-DIEA) is an excellent resin bound alternative to diethylamine]. Solvents are then evaporated at 65 °C to afford the cyclized products of formula(II).


EXAMPLE 4

10 General Solid Phase Synthesis of Compounds of Formula (II) using the Ugi reaction and resin (IXa)

(60mg) of resin (IXa) is pre-swelled with THF. 0.5M solutions of the appropriate aldehyde (XV) (10 equiv.), amine (XVI) (10 equiv.) and carboxylic acid (XXII) (10 equiv.) in THF:MeOH (1:1) are added sequentially to the resin (IXa) and the reaction stirred at room temperature for 3 days.

15 The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi product (XXIII). Treatment with BOC₂O (10 equiv.), Et₃N (10 equiv.) and DMAP in CH₂Cl₂ (15 hours) affords the activated resin bound product (XXIV) for cleavage. Sodium methoxide (5mg) in THF: MeOH, 1:1, is added to the resin and shaken for 20 hours. The solvent is evaporated in vacuo to give the desired methyl ester (XXV). The
20 deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and a 5% solution of diethylamine in dichloroethane [Note : 10-15 mg of N,N-(diisopropyl)amino-methylpolystyrene (PS-DIEA) is an excellent resin bound alternative to diethylamine]. Solvents are then evaporated at 65 °C to afford the cyclized product of formula (II). Examples of products (examples 29 to 33)
25 synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m C18 4.6X50mm 0.1%TFA in H₂O/CH₃N 10% to 100% CH₃N 5 min, at a rate of 1ml/min for 29-33. Desired products are seen as (M+ 1).

30




Compound	Retention time	Mass spec	ELSD A%	UV (220 nm) A%
29	3.19 & 3.36	416	100	71
30	3.10	443	94	68
31	2.80	261	100	95
32	3.10 & 3.76	304	98	89
33	3.02 & 3.10	354	71	56

5 EXAMPLE 5

Solution Phase Synthesis of Compounds of Formula (III) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:

- 10 Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components compound of formulae (XXVI), (XXVII), (XV) and (IXb), are employed generating a theoretical 10 μ mol of final product for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 $^{\circ}$ C (using a SAVANT[®] evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and a 5% solution of diethylamine in dichloroethane [Note : 10-15 mg of N,N-(diisopropyl)amino-methylpolystyrene (PS-DIEA) is an excellent resin bound alternative to diethylamine]. Solvents are then evaporated at 65 $^{\circ}$ C to afford the cyclized product of formula (III). Examples of
- 15


products (examples 34 to 45) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 2.1 x 50 mm column (UV 220 nm) with a mobile phase of 0.1% TFA in CH₃CN/H₂O, gradient from 10% CH₃CN to 100% over 5 min. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products seen as (M+1).



Compound	Retention time	Mass spec	UV (220 nm) A%
34	6.66	398	77
35	1.06	248	97
36	4.09	394	92
37	3.35	282	77
38	2.91	324	77

39	2.38	262	69
40	4.14	412	83
41	5.07	474	70
42	4.60	428	80
43	5.26	488	85
44	5.19	446	66
45a	5.14	460	30

The following compounds could potentially be made using the same protocol :-



General Procedure and ^1H for compound 34

5 Stoichiometric amounts (2 ml) of 0.1 M solutions of the four appropriate Ugi components are combined and stirred at room temperature overnight. The solvent is evaporated *in vacuo* and the residue is dried under high vacuum. A 10% solution of AcCl in MeOH (8 ml) is added to the crude material and stirred at room temperature overnight. The solvent is evaporated *in vacuo*. A 5% solution of diethylamine in dichloroethane is then added to the crude material and the


10 solution shaken overnight at room temperature. The solvent is evaporated *in vacuo* and crude material pre-absorbed onto flash silica and purified by column chromatography to yield the desired ketopiperazine, 34, (44 mg, 55%) as a white solid : mp 188-190°C. For major conformer only: ^1H (CDCl₃) 7.90 (1H, s, NH), 7.10-7.40 (15H, m, C₆H₅ x 3), 5.60 (1H, s, CHC₆H₅), 4.78-4.83 (1H, m, CHCH₂), 4.05-4.12, 3.31-3.40 (2H, 2x m, CH₂N), 2.98-3.02, 2.80-2.88 (2H, 2x m, CH₂N), 2.50-2.60 (2H, m, CH₂C₆H₅), 1.90-2.00, 2.03-2.10 (2H, CH₂). For major conformer only:

15 ^{13}C (CDCl₃) 170.2, 168.7, 141.4, 139.8, 128.7, 128.4, 128.3, 126.7, 125.8, 54.5, 53.0, 39.2, 32.9, 31.7. IR (KBr disc) 3260m, 1641s, 1620s (selected peaks only). mspec (APCI) 399 (MH⁺), 371. ^1H and ^{13}C assignments have been obtained from ^1H , ^{13}C , DEPT, COSY, HMQC and HMBC experiments. The ^1H and ^{13}C spectra show two sets of resonances throughout the spectrum.


20 Exchange crosspeaks between major and minor forms are observed in a rotating frame Overhauser effect spectroscopy (ROESY). These resonances also show broadening at temperatures above 80°C. These experiments show that the two forms are in slow exchange under the present experimental conditions. HMBC spectrum showed correlation between the methylene protons(H₂ and H₂') with the carbonyl carbon C6 confirming the ring closure.

EXAMPLE 6**General Solid Phase Synthesis of Compounds of Formula (III) using the Ugi reaction and resin (IXa)**


- (60mg) of resin (IXa) is pre-swelled with THF. 0.5M solutions of the appropriate aldehyde (XV) (10 equiv.), diamine (XXVII) (10 equiv.) and carboxylic acid (XXVI) (10 equiv.) in THF:MeOH (1:1) are added sequentially to the resin (IXa) and the reaction stirred at room temperature for 3 days. The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi product (XXX). Treatment with BOC₂O (10 equiv.), Et₃N (10 equiv.) and DMAP in CH₂Cl₂ (15 hours) afford the activated the resin bound product (XXVII) for cleavage. Sodium methoxide (5mg) in THF: MeOH, 1:1, is added to the resin and shaken for 20 hours. The solvent is evaporated in vacuo to give the desired methyl ester (XXXI). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane. Solvents are then evaporated at 65 °C to afford the cyclized product of formula (III). Examples of products (examples 46 to 51) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a Hypersil BDS 3 m C18 4.6X50mm 0.1%TFA in H₂O/CH₃N 10% to 100% CH₃N 5 min, at a rate of 1ml/min for 46-49 and 51. C18 Hypersil BDS 3 m C18 4.6X50mm 0.1%TFA in H₂O/CH₃N 5% to 100% CH₃N 5 min, at a rate of 1ml/min for 52. Desired products are seen as (M+ 1).




46




47




48




49



50



51




Compound	Retention time	Mass spec	ELSD A%	UV (220 nm) A%
46	3.54	318	100%	100%
47	3.63	368	100%	100%
48	2.80	348	100%	94%
49	4.19	380	100%	100%
50	7.55	398	100%	77%
51	5.19	446	80%	86%
52	4.06	410	100%	90%

EXAMPLE 7

- 5 General Solution Phase Synthesis of Compounds of Formula (IV) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:

Equal amounts (0.1 ml) of 0.1 M solutions of the four appropriate components compounds of formulae (IX), (XV), (XVI) and (XXXIII) are employed generating a theoretical 10 μ mol of dihydroimidazole product (IV) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 °C (using a SAVANT[®] evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane. Solvents are then evaporated at 65 °C to afford the cyclized product of formula (IV). The non-cyclized amines were removed via a solution phase scavenging step with the simultaneous addition of PS-DIEA or PS-tris(2-aminoethyl)amine (6 equiv.) and PS-NCO (3 equiv.) in dichloroethane. (Booth, R.J.; Hodges, J.C. *J. Am. Chem. Soc.* 1997, 119, 4882. Flynn, D.L.; Crich, J. Z.; Devraj, R. V.; Hockerman, S.L.; Parlow, J.J.; South, M.S.; Woodward, S. *J. Am. Chem. Soc.* 1997, 119, 4874. Purchased from Argonaut[®] technologies (PS-DIEA - polystyrene bound diisopropylethylamine)). Examples of products (examples 53 to 61) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector)

A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 10% to 100% 15 min, at a rate of 1ml/min for 3, 6, 7, 9, 10 and 11. BDS Hyp. 3 m C18 4.6X50mm 0.1% TFA IN H₂O/CH₃CN 10% to 100% 5 min, at a rate of 1ml/min for 4, 5, 8. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).





Compound	Retention time	mass spec	UV (220 nm) A%
53	7.36 & 8.05	625	40
54	4.87 & 5.08	493	66
55	4.58	451	60
56	11.26 & 1.57	697	67
57	6.36 & 6.84	565	59
58	4.86 & 5.03	525	79
59	8.53	605	56
60	10.0 & 10.22	615	48

61	8.05 & 8.88	665	71
----	-------------	-----	----

EXAMPLE 8**General Solid Phase Synthesis of Compounds of Formula (V) using the Ugi reaction and resin (XVIII)**

5 (60mg) of resin (XVIII) is pre-swelled with THF. 0.5M solutions of the appropriate aldehyde (XV) (10 equiv.), N-BOC-amino aldehyde (XXXV) (10 equiv.) and amine (XVI) (10 equiv.) in THF:MeOH (1:1) are added sequentially to the resin (XVIII) and the reaction stirred in methanol at room temperature and the solvent evaporated at 65 °C (using a SAVANT®
0 evaporator for 2 hours). The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi product (XXXVI). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane. Cyclization is then effected by base treatment with a 5% solution of diethylamine in dichloroethane [Note : 10-15 mg of
5 N,N-(diisopropyl)amino-methylpolystyrene (PS-DIEA) is an excellent resin bound alternative to diethylamine]. Solvents are then evaporated at 65 °C to afford the cyclized products. Examples of products synthesized using this general methodology are indicated below. Lc/ms (liquid chromatography/mass spectrometry) analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 10% to 100%
10 15 min, at a rate of 1ml/min for 62. Hypersil BDS 3 m C18 4.6X50mm 0.1% TFA IN H₂O/CH₃CN 10% to 100% 5 min, at a rate of 1ml/min for 63 to 72. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).






Compound	Retention time	mass spec	Compound	Retention time	mass spec
62	4.88	402	68	10.75	492
63	4.34	386	69	15.79	476
64	4.30	328	70	16.59	432
65	3.33	405	71	11.22	495
66	3.47	338	72	16.86	454
67	4.56	364			

Example 9


- 5 General Solution Phase Synthesis of 1,4-benzodiazepine-2,5-dione Compounds of Formula (VI) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:

Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components, ethyl glyoxalate (XXXVII), compound of formulae (XIV), (XVI) and (IX), are employed generating a theoretical 10 μ mol of final 1,4-benzodiazepine-2,5-dione product (VI) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 $^{\circ}$ C (using a SAVANT[®] evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the cyclized products. Examples of products (examples 62 to 72) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A%. Lc/ms (liquid chromatography/mass spectrometry) analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 10% to 100% 5 min, at a rate of 1 ml/min. HPLC is


interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).




73




74




75




76




77




78



79



80



81

5

Compound	Retention time	mass spec	ELSD A%
73	4.26	419	82
74	4.93	449	83
75	4.10	427	90
76	4.06	405	89
77	3.16	317	39
78	4.00	393	27
79	4.47	411	63
80	4.30	455	60
81	3.97	399	84


Example 10

General Solid Phase Synthesis of Compounds of Formula (VII) using the Ugi reaction and Resin Bound Amine (XXXIX)

- Wang bound Fmoc-amino acids (XXXIX) (100mg : loading of 0.70mmol/g) are treated with 20% piperidine in DMF (1 ml) at room temperature for one hour and washed with DMF (x3) and CH₂Cl₂ (x3). To each reaction vessel containing (XXXIX) is added 0.8 ml of CH₂Cl₂, followed by 0.1M solutions in MeOH of the appropriate aldehydes (XV) (5 equiv.), isonitriles (IX) (5 equiv.) and anthranilic acid (XIV) (5 equiv.). The reactions are shaken overnight at room temperature and washed with methanol (x3) and CH₂Cl₂ (x3). Each resin is then treated with 10% TFA in CH₂Cl₂ at room temperature for 3 hours (1.3 ml), then washed with CH₂Cl₂ (x2).
- The samples are then evaporated in a SAVANT at room temperature for 3 hours to give the crude products. Examples of products (examples 82 to 93) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A%. Lc/ms (liquid chromatography/mass spectrometry) analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 20% to 100% 20 min, at a rate of 1ml/min. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).

The following specific procedure is followed for compound 82 :-



- Wang bound Fmoc-Phenylalanine (100mg : loading of 0.70mmol/g) is treated with 20% piperidine in DMF (1 ml) at room temperature for one hour and washed with DMF (x3) and CH₂Cl₂ (x3). To each reaction vessel is added 0.8 ml of CH₂Cl₂, followed by 0.1M solutions in MeOH of phenpropionaldehyde (46µl, 5 equiv.), benzyl isocyanide (43µl, 5 equiv.) and N-BOC anthranilic acid (83mg, 5 equiv.). The reactions are shaken overnight at room temperature and washed with methanol (x3) and CH₂Cl₂ (x3). Each resin is then treated with 10% TFA in CH₂Cl₂ at room temperature for 3 hours (1.3 ml), then washed with CH₂Cl₂ (x2). The sample is then evaporated in a SAVANT at room temperature for 3 hours to give 20mg of crude product.



Compound	Retention time	Mass spec	ELSD A%
82	10.45	517	70
83	4.64	499	95
84	7.14, 7.37	407	97
85	3.83	523	95
86	3.50	391	50
87	4.14	463	100
88	3.80, 3.97	464	95
89	5.67	488	41
90	5.90, 6.10	507	44
91	5.10	605	44
92	5.36	461	100
93	9.38 & 10.35	481	100

Example 11General Solid Phase Synthesis of Acids by Hydroxide Clipping of Resin Bound Safety Catch Linker (IXa)

(60mg) of resin (IXa) is pre-swelled with THF. 0.5M solutions of the appropriate aldehyde (XV) (10 equiv.), amine (2-(5-imidazole)ethylamine or 3-(1pyrrolidine)propylamine) (10 equiv.) and carboxylic acid (XXVI) (10 equiv.) in THF:MeOH (1:1) are added sequentially to the resin (IXa) and the reaction stirred at room temperature for 3 days. The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi products. Treatment with BOC₂O (10 equiv.), Et₃N (10 equiv.) and DMAP in CH₂Cl₂ (15 hours) afford the activated the resin bound product. Sodium hydroxide (5mg) in THF:H₂O, 1:1, is added to the resin and shaken for 20 hours. The solvent is evaporated in vacuo to afford the desired acid, where lc/ms (liquid chromatography/mass spectrometry) A% purities are judged by ELSD (evaporative light scattering detector) A%. Lc/ms analysis is performed using a Hypersil BDS 3μ C18 4.6X50mm 0.1%TFA in H₂O/CH₃N 5% to 100% CH₃N 5 min, at a rate of 1ml/min. Desired products are seen as (M+ 1). Examples of acids synthesized using this general methodology are:




Compound	Retention time	mass spec	ELSD A%
94	4.80	485	100
95	4.23	484	89

Example 12

General Solution Phase Synthesis of Diketopiperazine Compounds of Formula (VI) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:

Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components compound of formulae (XIV), (XXXVII), (XVI) and (IX), are employed generating a theoretical 10 μ mol of final 1 Diketopiperazine product (VI) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 °C (using a SAVANT® evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the cyclized products. Examples of products (examples 96 to 112) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 10% to 100% 5 min, at a rate of 1ml/min (Examples 96 to 99), or a mobile phase 5mM NH₄OAC.H₂O/CH₃CN 10% to 100% 5 min, at a rate of 1ml/min (Examples 100 to 112),. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).

Compound	UV (220 nm) A%	ELSD A%	Retention Time (min)	Mass spec
96	80	70	4.33	421
97	75	90	3.80	379
98	81	90	4.27/4.40	419
99	80	90	3.83	379
100	86	100	3.13	303
101	86	100	4.90	495
102	84	100	4.57/4.80	469
103	92	100	4.33	4.60
104	72	100	3.29	3.53
105	83	100	3.57	3.80
106	81	100	4.75	4.53/4.77
107	82	100	3.43	3.67
108	88	100	4.49	4.39/4.49
109	95	70	4.99	3.89/3.96
110	80	90	3.88/4.22	521
111	70	86	3.78/3.51	476
112	63	84	3.50/3.63	538

**Example 13**


General Solution Phase Synthesis of Ketopiperazine Derivatives of Formula (VIII) via the '2-step, one pot' procedure, employing the Ugi multi-component reaction:


Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components of formulae (XXVI), (XXXVII), (XXVIIa) and (IX) are employed generating a theoretical 10 μ mol of final product (VIII) for 100% conversion. The 4-component condensation is performed in methanol at room temperature followed by increased heating, to afford the cyclized products. Examples of products (examples 113 to 122) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD

(evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 10% to 100% 5 min, at a rate of 1ml/min. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).

5

Compound	UV (220 nm) A%	ELSD A%	Mass spec	Retention Time (min)
114	41%	90%	427	4.17
115	43%	97%	331	3.53
116	35%	96%	303	2.90
117	32%	94%	349	3.97
118 cis	41%	90%	481	4.60
118 trans	70%	99%	481	4.63
119 cis	43%	97%	385	3.36/3.83
119 trans	47%	100%	385	4.09
120 cis	35%	96%	357	3.36/3.46
120 trans	34%	100%	357	3.63
121 cis	32%	94%	403	4.37/4.54
121 trans	57%	100%	403	4.67
122	75%	100%	351	3.29






122

Example 14

General Solution Phase Synthesis of Ketopiperazine Derivatives of Formula (VIII) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:


Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components, compound of formulae (XXVI), (XXXVII), (XXVII) and (IX), are employed generating a theoretical 10 μ mol of final Ketopiperazine product (VIII) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 $^{\circ}$ C (using a SAVANT[®] evaporator for 2 hours). The deprotection/cyclization steps are performed using the intermediate (XLI) and either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the acyclic products. MP-carbonate (3 equiv.) in dichloroethane (0.4ml) is added to the crude product and stirred overnight. The resin is filtered and washed with dichloroethane and then the filtrate is evaporated at 65 $^{\circ}$ C for 2 hours. Examples of products (examples 123 to 129) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%.. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase :- 0.1% AQ/ACN 10% to 100%, 5 min. (Compounds 123 and 124); 0.1% AQ/ACN 0% to 100%, 10min (compounds 125-128). HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).

Compound	UV (220 nm) A%	ELSD A%	Mass spec	Retention Time (min)
123	85	100	379	4.05
124	46	78	441	4.30
125	50	77	379	3.82
126	52	31	447	4.84
127	94	100	517	4.93
128	62	79	441	4.37


**Example 15****5 General Solution Phase Synthesis of Dihydroquinoxalinone Derivatives of Formula (VIII) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:**

Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components, compound of formulae (XXVI), (XXXVII), (XXVII) and (IX), are employed generating a theoretical 10 μ mol of final Dihydroquinoxalinone product (VIII) for 100% conversion. The 4-component
 0 condensation is performed in methanol at room temperature and the solvent evaporated at 65 $^{\circ}$ C (using a SAVANT[®] evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the cyclized products. Examples of products
 5 synthesized and further examples of other products which could be formed using this general methodology are indicated below. Examples of products (examples 129 to 131) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220
 10 nm) with a mobile 0.1% AQ/ACN 0% to 100%, 5 min. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).


Compound	UV (220 nm) A%	ELSD A%	Mass spec	Retention Time (min)
129	30	28	467	5.17
130	40	43	367	3.03
131	30	20	405	4.04



129




130



131

The following compounds can also be made by the same process:




5 Example 16

General Solid Phase Synthesis of Ketopiperazine Derivatives of Formula (XLII) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:


Wang bound Fmoc-amino acids (XXXIX) (100mg : loading of 0.70mmol/g) is treated with 20% piperidine in DMF (1 ml) at room temperature for one hour and washed with DMF (x3) and CH₂Cl₂ (x3). Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components, compound of formulae (XXVI), (XXXIX), (XLIII) and (IX), are employed generating a theoretical 10 μ mol of final Ketopiperazine product (XLII) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 °C (using a SAVANT® evaporator for 2 hours). The deprotection/cyclization steps are performed using the intermediate (XLIX) and either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the

cyclized products. Examples of products synthesized using this general methodology are indicated below. Examples of products (examples 132 to 139) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase :- 0.1% AQ/ACN 10% to 100%, 5 min. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).


Compound	UV (220 nm) A%	ELSD A%	Mass Spec	Retention Time (Min)
132	57	67	607	10.14
133	48	54	621	10.35/10.78
134	62	77	573	10.15
135	59	72	523	9.54
136	29	33	675	11.47
137	37	33	573	10.21
138	47	48	613	11.07
139	30	33	635	10.81



132




133




134

125

**EXAMPLE 17****5 General Solid Phase Synthesis of Piperazinyl Derivatives of Formula (Ia), using the Ugi reaction and resin (XVIII)**


(25mg) of resin (XVIII) is pre-swelled with THF. 0.5M solutions of the appropriate aldehyde (XVa) (10 equiv.), amine (XVIa) (10 equiv.), N-BOC anthranilic acid (XIV) (10 equiv.) in THF:MeOH (1:1) and NaHCO₃ (10 equiv.) are added sequentially to the resin (XVIII) and the reaction stirred at room temperature for 3 days. The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi intermediate (XVIIa). A 10% solution of acetyl chloride in THF : MeOH (1:1, 900ul) is added to the resin bound intermediate (XVIIa) and the reaction shaken for 24 hours. Solvents are then evaporated at 65 °C to afford the cyclized product of formula (Ia). Examples of products which are synthesized using this general methodology are indicated below.



where Y² = CH₃, CH₂CH₃, Phenyl, Benzyl, CH₂CH(CH₃)₂, CH(CH₃)₂.

EXAMPLE 18**General Solid Phase Synthesis of Piperazinyl Derivatives of Formula (IIa) using the Ugi reaction and resin (XVIII)**

- 5 (25mg) of resin (XVIII) is pre-swelled with THF. 0.5M solutions of the appropriate aldehyde (XVa) (10 equiv.), amine (XVIa) (10 equiv.), *N*-BOC-a-amino acid (XXII) (10 equiv.) in THF:MeOH (1:1) and NaHCO₃ (10 equiv.) are added sequentially to the resin (XVIII) and the reaction stirred at room temperature for 3 days. The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi intermediate (XXIIIa). A 10% solution of acetyl chloride in THF : MeOH (1:1, 900ul) is added to the resin bound Ugi intermediate (XXIIIa) and the reaction shaken for 24 hours. Solvents are then evaporated at 65 °C to afford the cyclized product of formula (IIa). Examples of products which are synthesized using this general methodology are indicated below.




- 5 where Y² = CH₃, CH₂CH₃, Phenyl, Benzyl, CH₂CH(CH₃)₂, CH(CH₃)₂.

EXAMPLE 19**General Solid Phase Synthesis of Lactam Derivatives of Formula (IIIa) using the Ugi reaction and resin (XVIII)**

- 10 (25mg) of resin (XVIII) is pre-swelled with THF. 0.5M solutions of the acid (XXVIa) (10 equiv.), amine (XXVII) (10 equiv.), in THF:MeOH (1:1) are added sequentially to the resin (XVIII) and the reaction stirred at room temperature for 3 days. The resin is washed sequentially with CH₂Cl₂, THF, DMF, THF and MeOH dried under high vacuum to yield the resin bound Ugi intermediate (XXVIIIa). A 10% solution of acetyl chloride in THF : MeOH (1:1, 900ul) is added to the resin bound intermediate (XXVIIIa) and the reaction shaken for 24 hours. Solvents are then evaporated at 65 °C to afford the intermediate salt. The intermediate salt is dissolved in

dichloroethane and MP-carbonate (5 equiv.) added. The reaction is shaken at room temperature for three days and the solvent evaporated in vacuo at 65°C to afford the desired cyclic products of general formula (IIIa). Examples of products which are synthesized using this general methodology are indicated below.


5




Example 20

General Solution Phase Synthesis of 1,4-benzodiazepine-2,5-dione Compounds of Formula (VI) via the '3-step, one pot' procedure, employing the Ugi multi-component reaction:

- 5 Equal amounts (0.1ml) of 0.1 M solutions of the four appropriate components, ethyl glyoxalate (XXXVII), an isonitrile of formula (XVI), an amine (XVI) and di-BOC protected *N*-mono-BOC arginine (XIV), are employed generating a theoretical 10 μ mol of final diketopiperazine product (VI) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65 °C (using a SAVANT® evaporator for 2 hours) .
- 0 The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the cyclized products. Examples of products (examples 140 to 160) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% . Lc/ms
- 5 (liquid chromatography/mass spectrometry) analysis is performed using a C18 Hypersil BDS 3 m 4.6X50mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H₂O/CH₃CN 10% to 100% 5 min, at a rate of 1ml/min. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+ 1).
- 0 HPLC conditions : 4.6 x 50 mmH.B. 3u c18 TFA0.1%AQ/ACN 10% to 100%, 4 mn.






Structure	Mw	ELSD A%	UV 220	R.T
1	476	100	43	2.84 ; 2.95
2	446	92	70	2.87
3	354	100	100	2.66
4	434	100	60	3.38
5	432	100	59	2.76
6	512	100	87	3.48
7	394	100	58	2.97
8	494	97	84	3.21
9	446	100	82	3.06
10	396	100	100	3.23
11	436	100	88	3.13
12	422	100	53	3.11
13	526	84	74	3.55
14	458	100	88	2.97
15	625	91	81	3.38
16	508	97	66	1.92
17	611	100	90	3.28
18	512	100	86	3.41
19	493	100	76	2.47
20	460	95	83	2.74
21	484	92	86	3.35


Example 21

5 Solid Phase Preparation of Cyclic Ureas of general formula (L)

The aldehyde (XV) (5ml, 0.3M solution in MeOH), the amine (XXVII) (5ml, 0.15M solution in MeOH) and the isocyanide (IX) (5ml, 0.15M solution in MeOH) are added sequentially to the reaction flask and the acid (LI) (generated in situ in the reaction flask by bubbling CO₂ through MeOH at 0°C five minutes), the reaction flask capped and the reaction allowed to warm to room temperature. The solution is then stirred at room temperature for 24 hours under an atmosphere of CO₂. The solution is evaporated under high vacuum at high temperature. The crude material is re-dissolved in dichloroethane and PS-TsNHNH₂ (5 mmol) is added to scavenge excess aldehyde. The solvent is evaporated under high vacuum. A 10% TFA solution in dichloroethane

(10ml) is added to the crude reaction and the reaction stirred for 24 hours at room temperature. The solution is then evaporated under high vacuum. An immobilized proton scavenger (e.g. MP-carbonate, PS-morpholine) is added (5 equiv.) in dichloroethane and the suspension shaken at room temperature for 3 days. The resin is then filtered and the solvent evaporated at high
5 temperature to yield the desired cyclic product (L). Below is are examples of compounds which are synthesized by this process.





**Example 22****5 Solid Phase Preparation of Cyclic Ureas of General Formula (LIII)**

The aldehyde (XXXIII)(5ml, 0.3M solution in MeOH), the amine (XVI)(5ml, 0.15M solution in MeOH) and the isocyanide (IX) (5ml, 0.15M solution in MeOH) are added sequentially to the reaction flask and stirred at 0°C. The acid (LI) is generated in the reaction flask by bubbling through the solution for five minutes, the reaction flask capped and the reaction allowed to warm to room temperature. The solution is then stirred at room temperature for 24 hours under an atmosphere of

10

CO₂. The solution is evaporated under high vacuum at high temperature to afford the intermediate (LIV). The crude material is re-dissolved in dichloroethane and PS-TsNHNH₂ (5 mmol) is added to scavenge excess aldehyde. The solvent is evaporated under high vacuum. A 10% TFA solution in dichloroethane (10ml) is added to the crude reaction and the reaction stirred for 24 hours at room temperature. The solution is then evaporated under high vacuum. An immobilized proton scavenger (eg MP-carbonate, PS-morpholine) is added (5 equiv.) in dichloroethane and the suspension shaken at room temperature for 3 days. The resin is then filtered and the solvent evaporated at high temperature to yield the desired cyclic product of general formula (LIV). Examples of the products formed by this process are listed below.






Example 23

5 Solution Phase Preparation of hydanoins of general formula (LV)


Phenpropionaldehyde (XV) (5ml, 0.3M solution in MeOH), para-methoxybenzyl amine (XVI) (5ml, 0.15M solution in MeOH) and cyclohexylisocyanide (IX) (5ml, 0.15M solution in MeOH) are added sequentially to the reaction flask and stirred at 0°C. The acid (LI) is generated in the reaction flask by bubbling through the solution for five minutes, the reaction flask capped and the reaction allowed to warm to room temperature. The solution is then stirred at room temperature for 24 hours under an atmosphere of CO₂. The solution is evaporated under high vacuum at high temperature. A 1N solution of KOH in MeOH was added to the crude material and the reaction shaken overnight at room temperature. The solvent was then evaporated at 65°C under high vacuum to afford the product 161.



161

FAB 407 (MH⁺). ¹³C (CDCl₃) 25.06, 25.86, 25.89, 29.15, 29.38, 29.54, 30.34, 44.38, 55.31, 57.74, 114.32, 126.23, 127.96, 127.96, 128.37, 128.49, 156.72, 159.41, 172.75

Similarly, the following compounds can be made using the above methodology and the appropriate acid (LI), aldehyde (XXXIII) amine (XVI) and isocyanide (IX)





5





Example 24

Solution Phase Preparation of compounds 162 and 163

100 microlitres of 0.1M solutions of the *N*-BOC anthranilic acid, phenpropionaldehyde, cyclohexylisocyanide and the methyl ester of phenylalanine in MeOH were stirred at room temperature for 2 days. The solvent was evaporated in vacuo at 65°C to give Ugi intermediate, 162. The product was treated with 400ul of 10% AcCl in methanol solution (alternatively a 10% TFA solution in 1,2-dichloroethane could be used). The reaction was stirred for 24 hours and the solvent evaporated in vacuo to give the product, 163.

**Example 25****Solution Phase Preparation of compounds 164, 165, 166 and 167**


100 microlitres of 0.1M solutions of the *N*-BOC α -amino aldehyde, diphenylacetic acid,
 5 cyclohexylisocyanide and the methyl ester of phenylalanine in MeOH were stirred at room
 temperature for 2 days. The solvent was evaporated in vacuo at 65C to give Ugi intermediates,
 164. The product was treated with 400ul of 10% AcCl in methanol solution (alternatively a 10%
 TFA solution in 1,2-dichloroethane could be used). The reaction was stirred for 24 hours and the
 solvent evaporated in vacuo to give the products, 165 - 167 .



The present invention may be embodied in other specific forms without departing from
 the spirit or essential attributes thereof.


WHAT IS CLAIMED IS:

1. A method for preparing an N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound of the formula



(A)


wherein

 R_{aa} is

R_{aa} is hydrogen, alkoxy, an optionally substituted aliphatic moiety or an optionally substituted aromatic moiety;

R_b is hydrogen, an optionally substituted aliphatic moiety or an optionally substituted aromatic moiety;

R_{ca} and R_{cb} are independently hydrogen, an optionally substituted aliphatic moiety or an optionally substituted aromatic moiety;

 R_d is

; and

R_{da} is an optionally substituted aliphatic moiety or an optionally substituted aromatic moiety; and wherein either

R_{aa} is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with the $*_{ab}$ or $*_{db}$ carbon, or with at least one R_b , R_{ca}

and R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring; or

5 R_b is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with the $*ab$ or $*db$ carbon, or with at least one R_{aa} , R_{ca} and R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring; or


10 at least one of R_{ca} and R_{cb} is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with the $*ab$ or $*db$ carbon, or with at least one R_{aa} , R_b , R_{ca} , R_{cb} and R_{da} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring; or

15 R_{da} is an aliphatic or aromatic moiety that is substituted with a primary or secondary protected amine that, upon deprotection, can react with at least one of R_{ca} and R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring,

20 provided that, when R_{aa} is substituted with a primary or secondary protected amine that, upon deprotection, can react with R_b (substituted with an activated carboxylic acid), then R_{aa} is substituted aromatic,

this method comprising reacting:

25 (i) a carbonyl compound of formula



with

(ii) an amine compound of formula

30 NH_2R_b [C],

(iii) an isonitrile compound of formula

35 NCR_{da} (D), and

(iv) an acid compound of formula



5 to produce the N-[(aliphatic or aromatic)carbonyl]]-2-aminoacetamide compound.


2. The method according to claim 1 wherein R_{aa} is substituted with a primary or secondary protected amine that, upon deprotection, can react with the *db carbon, or with at least one of R_{ca} or R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring.


3. The method according to claim 1 wherein R_{aa} is substituted with a primary or secondary protected amine that upon deprotection can react with R_b , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring.

4. The method according to claim 1 wherein R_b is substituted with a primary or secondary protected amine that, upon deprotection, can react with the *db carbon, or with at least one of R_{ca} or R_{cb} , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring.

5. The method according to claim 1 wherein at least one of R_{ca} and R_{cb} is substituted with a primary or secondary protected amine that, upon deprotection, can react with the *ab or *db carbon, or with R_b , which is substituted with an activated carboxylic acid, to form a 5-7 membered cyclic ring.

6. The method according to claim 1 further comprising deprotecting and cyclizing the N-[(aliphatic or aromatic)carbonyl]]-2-aminoacetamide compound of formula (A) to afford a cyclized compound having a formula selected from the group consisting of:





5

wherein:

n = 1 or 2;

m = 0 or 1;

p = 2;

.0 q = 1 or 2;

R¹ and R⁹ independently are selected from hydrogen, alkenyl, alkyl, aralkenyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl, and heterocyclyl;

R² is selected from hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl and heterocyclyl, or

.0

R^1 and R^2 , taken together with the nitrogen atom and carbon atoms through which R^1 and R^2 are linked, form a 6 membered heterocyclyl ring;

5 R^3 is selected from hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heterocyclenyl and heterocyclyl;

10 R^4 and R^5 independently are selected from hydrogen, alkenyl, alkyl, aryl, alkynyl, aralkenyl, aralkynyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaralkenyl, heteroaralkynyl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl and heterocyclenyl, or
 5 R^4 and R^5 , taken together with the carbon atom through which R^4 and R^5 are linked, form a 3 to 7 membered cycloalkyl or cycloalkenyl ring;

R^6 , R^7 , R^8 and R^8 independently are selected from hydrogen, alkenyl, alkenyloxy, alkoxy, alkyl, aryl, alkylsulfinylcarbonyl, alkynyl, alkynyloxy, aralkenyl, aralkylsulfonyl, aralkynyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, arylloxycarbonyl, cycloalkyloxy, heteroaralkenyl, heteroaralkyloxy, heteroaralkynyl, heteroaroyl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heteroarylsulphonylcarbonyl, heterocycliloxy, heteroaryl, aralkyl, heteroaralkyl, hydroxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxy, carbonyl, aryloxy, carbonyl, aralkoxy, carbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, arylidazo, heteroarylidazo, amidino, Y^1Y^2N- , Y^1Y^2NCO- and $Y^1Y^2NSO_2-$,
 10 wherein Y^1 and Y^2 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or, where the substituent is Y^1Y^2N- , then one of Y^1 and Y^2 is acyl or aroyl and the other of Y^1 and Y^2 is as defined previously, or, where the substituent is Y^1Y^2NCO- or $Y^1Y^2NSO_2-$, Y^1 and Y^2 , taken together with the N atom through which Y^1 and Y^2 are linked, form a 4 to 7 membered heterocyclyl or heterocyclenyl ring, or

R^3 and R^8 , taken together with the nitrogen atom and carbon atoms through which R^3 and R^8 are linked, form a 5 to 7 membered heterocyclyl or heterocyclenyl ring, or
 15 two adjacent substituents selected from the substituents R^6 , R^7 , R^8 and R^8 , taken together with the aryl carbon atoms through which the two adjacent substituents are linked, form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl, or 6 membered aryl or 5 or 6 membered heteroaryl ring;

R^{14} , R^{15} , R^{10} and R^{11} independently are selected from hydrogen, alkenyl, alkyl, aryl, alkynyl, aralkenyl, aralkynyl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaralkenyl, heteroaralkynyl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heteroarylsulphonylcarbamoyl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, or,

when $n=1$, and R^{11} and R^{14} are absent, R^{10} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 6 membered aryl or 5 or 6 membered heteroaryl ring;

or, when $n=1$, and R^{11} and R^{14} are present, R^{10} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl ring;

or, when $n=2$, and adjacent R^{11} and R^{14} are absent, R^{10} and adjacent R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 6 membered aryl or 5 to 6 membered heteroaryl ring;

or when $n=2$, and R^{11} and R^{14} are present, R^{10} and adjacent R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl ring;

or when n or $p=2$, and the adjacent R^{14} and R^{14} are absent, the adjacent R^{15} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 6 membered aryl or 5 or 6 membered heteroaryl ring;

or when n or $p=2$, and the adjacent R^{14} and R^{14} are present, adjacent R^{15} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl ring;

or, when $m=1$, and R^{11} and R^{14} are absent, R^{10} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 6 membered aryl or 5 or 6 membered heteroaryl ring;

or, when $m=1$, and R^{11} and R^{14} are present, R^{10} and R^{15} , taken together with the adjacent carbon atoms through which they are linked, form a 5 to 7 membered cycloalkyl or a cycloalkenyl, heterocyclyl or heterocyclenyl ring;

R^{12} is selected from alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclenyl, fused heteroarylheterocyclyl, heterocyclenyl and heterocyclyl; and

- R^{16} is selected from hydrogen, alkenyl, alkyl, aralkyl, aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, heteroaralkenyl, fused arylheterocyclyl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, fused heteroaryl cycloalkenyl, fused heteroaryl cycloalkyl, fused heteroaryl heterocyclenyl, fused heteroaryl heterocyclyl, heterocyclenyl and heterocyclyl, or
- 5 R^9 and R^{16} , together with the carbon atoms and nitrogen atom through which they are linked, form a 5-8 membered heterocyclyl ring.

7. The method according to claim 6, wherein the acid compound is of formula




(XIV) wherein Z^1 is a suitable amine protecting group;

- 0 the carbonyl compound is of formula



the isonitrile compound is of formula




(IX) ; and

- 5 the amine compound is of formula




8. The method according to claim 7 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula
- 10




9. The method according to claim 6 wherein the cyclized product is

143




10. The method according to claim 6, wherein the acid compound is of formula




(XIV) wherein Z^1 is a suitable amine protecting group;


the carbonyl compound is of formula



the isonitrile compound is selected from the group of formulae



and




(XVIII), wherein \bigcirc

is a solid support resin; and


the amine compound is of formula




11. The method according to claim 6 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula



12. The method according to claim 11 wherein the cyclized compound is of the formula




13. The method according to claim 6, wherein
the acid compound is of formula



(XXII)


wherein Z¹ is a suitable amine protecting group;

- 5 the carbonyl compound is of formula



(XV) ;

the isonitrile compound is of formula



(IX) ;


- 10 and the amine compound is of formula



(XVI)


14. The method as claimed in claim 13 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula

15




(XXIII)

15. The method according to claim 14, wherein the cyclized compound is of the formula



(II)

16. The method according to claim 6, wherein the acid compound is of formula




- 5 wherein Z^1 is a suitable amine protecting group;

the carbonyl compound is of formula



- 0 the isonitrile compound is of formula




and the amine compound is of formula




5

17. The method as claimed in claim 16 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula



18. The method according to claim 6, wherein the acid compound is of formula




10

the carbonyl compound is of formula




15

the isonitrile compound is of formula




and the amine compound is of formula



(XXVII) wherein Z¹ is a suitable amine protecting group.


5

19. The method as claimed in claim 18 wherein the N-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compound is of the formula




(XXVIII)

0 20. The method according to claim 19, wherein the cyclized compound is of the formula



(III)

5 21. The method according to claim 6, wherein the acid compound is of formula



(XXVI)

the carbonyl compound is of formula


10




(XV)

the isonitrile compound is of formula

147




and the amine compound is of formula




(XXVII) wherein Z¹ is a suitable amine protecting group.

5


22. The method according to claim 21 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula



23. The method according to claim 6, wherein the acid compound is of formula




the carbonyl compound is of the formula




15

wherein Z¹ is a suitable amine protecting group.;

the isonitrile compound is of the formula




and the amine compound is of the formula




20


24. The method according to claim 23 wherein the N-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compound is of the formula




25. The method according to claim 24, wherein the cyclized compound is of the formula




26. The method according to claim 6, wherein the acid compound is of formula



wherein Z¹ is a suitable amine protecting group;
the carbonyl compound is of formula



the isonitrile compound is of formula




and the amine compound is of formula




(XVI)


27. The method according to claim 26 wherein the N-[(aliphatic or aromatic)carbonyl]]-2-aminoacetamide compound is of the formula



28. The method according to claim 27, wherein the cyclized compound is of the formula




29. The method according to claim 6, wherein the acid compound is of formula




wherein Z^1 is a suitable amine protecting group;

the carbonyl compound is of formula



the isonitrile compound is of formula




(IX) ; and


the amine compound is of formula



30. The method as claimed in claim 29 wherein the N-[(aliphatic or aromatic)carbonyl]]-2-aminoacetamide compound is of the formula



31. The method according to claim 6, wherein the acid compound is of formula




wherein Z¹ is a suitable amine protecting group;


the carbonyl compound is of formula



the isonitrile compound is selected from



and




wherein \bigcirc is a solid

support resin; and


the amine compound is of formula




32. The method according to claim 31 wherein the N-[(aliphatic or aromatic)carbonyl]]-2-aminoacetamide compound is of the formula




33. The method according to claim 6, wherein the acid compound is of formula



wherein Z^1 is a suitable amine protecting group; the carbonyl compound is of formula;



the isonitrile compound is selected from the group of formulae




wherein \ominus is a solid

support resin; and


the amine compound is of formula




34. The method as claimed in claim 33 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula




35. The method according to claim 6, wherein the acid compound is of formula




the carbonyl compound is of formula



wherein Z¹ is a suitable amine protecting group; the isonitrile compound is selected from





or




the amine compound is of formula



36. The method according to claim 35 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is selected from compounds of formulae




37. The method according to claim 36 wherein the cyclized product is




(V)

38. The method according to claim 6, wherein the acid compound is of formula




(XIV)

the carbonyl compound is of formula




(XXXVII)

the isonitrile compound is of formula




(IX)

the amine compound is of formula




(XVI)

39. The method according to claim 38 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula



(XXXVIII)


40. The method according to claim 6, wherein the acid compound is of formula



(XIV)


5

the carbonyl compound is of formula



(XXXVII)

the isonitrile compound is of formula




(XVIII)

10


; and

the amine compound is of formula




(XVI)

15 41. The method according to claim 40 wherein the N-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compound is of the formula




5

42. The method according to claim 6, wherein the acid compound is of formula




(XIV)

the carbonyl compound is of formula



(XV)


the isonitrile compound is of formula



(IX)


the amine compound is of formula

5




(XXXIX)

43. The method according to claim 42 wherein the N-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compound is of the formula




5


44. The method according to claim 43 wherein cyclized product is




45. The method according to claim 6, wherein the acid compound is of formula




the carbonyl compound is of formula



the isonitrile compound is of formula




the amine compound is of formula



(XXVII)


46. The method according to claim 45 wherein the N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound is of the formula

5



(XLI)


47. The method according to claim 46 wherein cyclized product is



(VIII)


.0

48. The method according to claim 6, wherein the acid compound is of formula



(XXVI)


the carbonyl compound is of formula



(XLIII);


.5

the isonitrile compound is of formula




(IX) ; and


the amine compound is of formula
















49. The method according to claim 48 wherein the N-[(aliphatic or aromatic)carbonyl]]-2-aminoacetamide compound is of the formula



















50. The method according to claim 49 wherein the cyclized product is of formula



















5 51. The method according to claim 6 wherein the cyclized product is selected from the group of formulae consisting of:































5











5


















wherein $Y^2 = \text{CH}_3, \text{CH}_2\text{CH}_3, \text{Phenyl}, \text{Benzyl}, \text{CH}_2\text{CH}(\text{CH}_3)_2, \text{ or } \text{CH}(\text{CH}_3)_2$.


5

52. A resin bound isonitrile selected from



(IXa)


and



(XVIII)

wherein \bigcirc is a solid support resin.

53. A resin bound amine compound of formula



0

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/21257

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07B61/00 C07C237/22 C07C231/14 C07D207/26 C07D233/54
 C07D241/44 C07D401/04 C07D403/04 C07D403/06 C07D405/06
 C07D409/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07B C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 38844 A (CHERRIER MARIE PIERRE ; HULME CHRISTOPHER (US); MORRISSETTE MATTHEW) 5 August 1999 (1999-08-05) the whole document	1-53
X	HULME C ET AL: "Novel Safety-Catch Linker and its Application with a Ugi/De-BOC/Cyclization (UDC) Strategy to access Carboxylic acids, 1,4-Benzodiazepines, Diketopiperazines, Ketopiperazines and Dihydroquinoxalinones" TETRAHEDRON LETTERS, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 39, no. 40, 1 October 1998 (1998-10-01), pages 7227-7230, XP004133645 ISSN: 0040-4039 the whole document	1-53

-/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "d" document member of the same patent family

Date of the actual completion of the international search

16 November 2000

Date of mailing of the international search report

22/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

O'Sullivan, P

INTERNATIONAL SEARCH REPORT

Interj nal Application No
PCT/US 00/21257

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HULME C ET AL: "The Solution Phase Synthesis of Diketopiperazine Libraries via the Ugi Reaction: Novel Application of Armstrong's Convertible Isonitrile" TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 39, no. 10, 5 March 1998 (1998-03-05), pages 1113-1116, XP004109131 ISSN: 0040-4039 page 1113, line 1 -page 1114, line 4</p>	1-53
A	<p>IVAR UGI ET AL: "Ugi Reactions with Trifunctional alpha-Aminoacids, Aldehydes, Isocyanides and Alcohols" TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 52, no. 35, 1 August 1996 (1996-08-01), pages 11657-11664, XP002084702 ISSN: 0040-4020 page 11659</p>	1-53
A	<p>HULME C ET AL: "Applications of N-BOC-Diamines for the Solution Phase Synthesis of Ketopiperazine Libraries Utilizing a Ugi/De-BOC/Cyclization (UDC) Strategy" TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 39, no. 44, 29 October 1998 (1998-10-29), pages 8047-8050, XP004138857 ISSN: 0040-4039 the whole document</p>	1-53
A	<p>DE 197 31 893 A (BOCK HOLGER ;LINDHORST THOMAS (DE); UGI IVAR PROF DR (DE)) 28 January 1999 (1999-01-28) claims</p>	1-53

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intel Patent Application No

PCT/US 00/21257

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9938844 A	05-08-1999	AU 2482199 A EP 1051397 A NO 20003792 A	16-08-1999 15-11-2000 27-09-2000
DE 19731893 A	28-01-1999	WO 9905093 A EP 1000016 A	04-02-1999 17-05-2000